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ABSTRACT 
Emphysema is a disease of the lung parenchyma associated with chronic 
obstructive pulmonary disease (COPD) and characterized by progressive, irreversible 
tissue destruction.  While chronic inflammation due to repeated noxious particle exposure 
is the most common environmental risk factor, biomechanical stresses are also known to 
contribute.  It is thought that inflammation-related enzymatic weakening predisposes tissue 
to mechanical failure, leading to self-propagating parenchymal destruction.  However, 
essential questions regarding the underlying disease mechanisms and their link to overall 
lung decline remain unanswered.  The overarching goals of this dissertation were to relate 
changes at the cell and tissue level to lung structure and function, and to determine how 
clinical interventions impact the mechanical balance of parenchymal tissue stresses.  First, 
we use a computational network model of lung volume reduction, a palliative treatment for 
end-stage emphysema, to demonstrate how recent bronchoscopic, biomaterial-based 
treatments can achieve similar outcomes as traditional surgical procedures.  Next, in a 
cohort of COPD patients with follow-up computed tomography (CT) imaging, we identify 
 vii 
a previously unrecognized structural feature of emphysema that suggests a fundamentally 
new mechanism of disease progression and potential target for tissue engineering solutions.  
Finally, we describe the design and implementation of an ex vivo platform for cyclic 
stretching of precision-cut lung slices, demonstrating a stretch-dependent inflammatory 
response to acute cigarette smoke extract exposure.  In summary, this work combines 
computational modeling, clinical imaging, and ex vivo measurements to characterize the 
biomechanical stresses driving emphysema progression and provide new insight that may 
inform more rational, patient-specific treatment strategies. 
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CHAPTER 1– Introduction 
 
1.1 Overview 
Emphysema is a disease of the lung parenchyma associated with chronic 
obstructive pulmonary disease (COPD) and characterized by progressive, irreversible 
tissue destruction [1], [2].  As the complex, intricate structure of the parenchyma is 
obliterated, the lungs become hyperinflated and the surface area for gas exchange 
decreases, causing breathing to be labored and inefficient.  Combined with concomitant 
small airway disease, these pathologic changes drive the hallmark feature of COPD – 
persistent airflow limitation leading to shortness of breath.  Emphysema typically presents 
later in life and is most commonly associated with a history of cigarette smoking [3], 
though genetic predisposition can also influence disease susceptibility and significantly 
accelerate the natural course of disease [4].  End-stage palliative therapies include surgical 
and non-surgical lung volume reduction treatment, which aim to improve lung function by 
directly or passively reducing more affected tissue regions [5], [6].  This debilitating 
condition, which affects more than 4.7 million people in the United States alone, represents 
a substantial burden on patients and health care expenditure overall [7], [8]. 
Despite considerable effort over the past several decades, our understanding of the 
mechanisms underlying disease progression remains incomplete [9].  The well-
documented protease-antiprotease imbalance hypothesis [10], [11] posits that emphysema 
arises from unchecked enzymatic tissue digestion following inhalation of noxious particles, 




process [12], including but not limited to, oxidative stress, apoptosis, increased numbers of 
inflammatory cells, and pro-inflammatory cytokines or other chemotactic factors [1].  A 
simplified schematic of this process is shown in Figure 1-1.  Equally important as these 
biological mediators, however, are the biomechanical stresses imposed by gravitational 
gradients and experienced by tissue during breathing [9], [13], [14].  Although such forces 
are typically insufficient in rupturing healthy tissue, enzymatic weakening of alveolar walls 
in emphysema predisposes tissue to rupture and mechanical failure.  Local redistribution 
of tissue stresses after mechanical failure is believed to further increase the risk of rupture 
in nearby lung regions [15], [16], a concept deriving from the seminal discovery that 
neighboring emphysema clusters tend to coalesce as disease severity worsens [17]. 
 
 




Appreciation for biomechanical stresses as a contributing factor in emphysema 
decline has grown in past years.  Recent studies have begun to uncover the functional 
impact of the altered mechanical environment in the emphysematous lung, developing new 
techniques to characterize the abnormal, heterogeneous forces in vivo that drive tissue 
destruction [16], [18].  The current understanding of disease progression assumes that 
emphysema advances via self-propagating, dynamic processes, which are enzymatically 
initiated but mechanically driven [15].  While this elegantly and concisely summarizes the 
appreciably complex disease process, specific details regarding the underlying 
pathophysiological mechanisms governing local tissue failure and their link to overall lung 
decline have yet to be adequately described.  Most notable is the fact that little attention 
has been dedicated to understanding the role of mechanotransduction-mediated changes in 
emphysema, despite its recognition in other fields such as vascular biology [9], [19].  
Consequently, important clinical questions, such as the effect of therapeutic interventions 
on the mechanical balance of tissue stresses in the lung, also remain unanswered.  Thus, 
we hypothesize that biomechanical forces govern tissue failure and acute 
inflammation in COPD, such that computational models can be used to predict 
disease progression.  Targeted intervention of mechanically abnormal lung regions 
could, therefore, define more patient-specific strategies to slow, or even reverse, 






1.2 Specific Aims 
The overarching theme of this dissertation is to study the effects of biomechanical 
stresses at the cell and tissue level, and on structural-functional changes throughout the 
entire lung.  To investigate this relatively broad topic, we rely on the following 
methodological approaches: (1) computational modeling of lung tissue mechanics; (2) 
computed tomography (CT) imaging; and (3) ex vivo animal models of disease.  The 
specific aims for this dissertation are described below. 
AIM 1: Develop a computational network model of surgical and bronchoscopic 
lung volume reduction to characterize the structure-function relations contributing to 
treatment efficacy.  We will simulate the elastic behavior of the lung parenchyma using a 
two-dimensional, computational network model of spring elements arranged as inter-
connected hexagonal units.  We will model emphysema progression by sequential 
elimination of elements carrying the highest forces, and then compare interventions with 
either surgical or bronchoscopic lung volume reduction treatment.  Immediate and long-
term patient outcomes, including survival and quality of life, will be predicted based on 
estimates of lung compliance and structure. 
AIM 2: Evaluate the sizes of CT low-attenuation volumes as a quantitative disease 
assessment during annual follow-up in patients with COPD.  We will reconstruct 3D lung 
representations from 2D axial CT slices obtained from a de-identified, observational COPD 
cohort database.  We will then characterize size distributions of low attenuation volumes, 
which represent individual clusters of low density emphysematous lung tissue, for patients 




the severity and pattern of emphysema will be correlated with clinical measures of lung 
function.  
AIM 3: Assess the mechano-inflammatory interaction in lung slices exposed to 
cigarette smoke extract during cyclic stretch.  We will design and validate a multi-well 
equibiaxial stretcher device to cyclically stretch precision-cut lung slices obtained from 
excised rat lungs.  Cigarette smoke extract will be used to mimic exposure to pro-
inflammatory chemicals in tobacco smoke during stretch.  Changes in tissue viability and 
cytokine production and secretion will be compared for different stretch patterns of lung 
slices with and without exposure to the smoke extract. 
 
1.3 Structure of Dissertation 
This dissertation is organized into six chapters and two supporting appendices.  
Chapter 2 provides a brief clinical overview of COPD and background in emphysema 
treatments, pathophysiology, and disease models relevant to the original work undertaken 
here.  In Chapter 3, we present a computational model of surgical and bronchoscopic lung 
volume reduction to predict treatment outcomes.  In Chapter 4, we explore CT-derived, 
structural features of emphysema progression during annual follow-up in patients with 
COPD.  We then move away from the clinic in Chapter 5 and describe a robust ex vivo 
platform for studying the effects of cyclic stretch in lung slices during acute exposure to 
cigarette smoke extract.  Finally, results and implications for the entirety of the work 
presented here, including recommendations for future investigations, are summarized in 









CHAPTER 2– Background 
 
2.1 COPD: Definition, Epidemiology, and Risk Factors 
COPD is a debilitating medical condition characterized by chronic dyspnea, or 
shortness of breath, secondary to airway obstruction.  Persistent airflow limitation is a 
hallmark of COPD primarily attributed to permanent destruction of the lung parenchyma 
and disease of the small airways [1].  However, individual phenotypes vary considerably 
among patients such that COPD is considered an umbrella term traditionally encompassing 
three main subtypes – chronic bronchitis, emphysema, and obstructive asthma [2].  
Interactions and overlap between these subtypes including their relation to COPD are 
illustrated in Figure 2-1. 
2.1.1 COPD is a Leading Global Health Concern 
This common yet presently incurable disease is associated with high morbidity and 
mortality, presenting a substantial economic as well as personal burden on the health care 
system and those affected [1], [8].  It is estimated that at least 65 million people suffer from 
COPD worldwide with nearly 90% of deaths occurring in low- and middle-income 
countries, a veritably sobering statistic [20].  In the U.S. alone, roughly 120,000 people die 
from COPD each year making it the third-leading cause of death nationally [21].  The 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) reports that the impact on 
the health care system is $29.5 billion in direct costs with an additional $20.4 billion in 
indirect costs [8].  Clearly, improved therapies and prevention strategies would help to 





Figure 2-1.  COPD comprises significant overlap and interaction between 
subtypes.  Diagram courtesy of the American Thoracic Society: COPD Today. 
 
2.1.2 Environmental Risk Factors 
Inhaled cigarette smoke is arguably the most well-known and best-studied risk 
factor for COPD; persons who smoke are 12-13 times more likely to die of the disease 
compared with those who do not smoke [7].  Smoking cessation, therefore, remains one of 
the most effective means of slowing disease progress [22].  However, according to the NIH 
only 1 in 4 smokers will develop clinical symptoms of COPD while roughly 20% of cases 
occur in those without a history of smoking, suggesting that other factors contribute to 
disease susceptibility [23].  Additional environmental risk factors summarized in the 
GOLD report [1] include cigar and pipe tobacco, secondhand smoke, air pollution related 




dust, and fumes.  Nevertheless, not all risk factors are necessarily related to exposure, some 
can instead be inherited. 
2.1.3 α1-Antitrypsin Deficiency Accounts for Only a Fraction of Overall Disease 
Perhaps the most thoroughly documented link between COPD susceptibility and 
genetic disorders is α1-antitrypsin deficiency [4], [10], [11], [24].  The circulating protein 
α1-antitrypsin blocks the action of proteinases to inhibit the elastase-mediated breakdown 
of lung tissue in the parenchyma.  For individuals with severe α1-antitrypsin deficiency, 
most frequently caused by a mutation in the SERPINA1 gene [24], the misfolded protein is 
unable to escape its site of production in the liver and its protective effects in the lung are 
lost, significantly increasing the risk for emphysema.  Although α1-antitrypsin deficiency 
accounts for only a small fraction of cases, between 1-5%, it represents a straightforward 
example of a genetic role in COPD [24].  Recently, considerable efforts have been made 
to better understand genetic contributions in COPD.  For example, the Genetic 
Epidemiology of COPD (COPDGene) Study [25] enrolled more than 10,000 patients in a 
prospective cohort to identify genetic factors and susceptibility genes associated with 
COPD.  Although beyond the scope of this dissertation, these efforts illustrate our evolving 
understanding of the risk factors involved in COPD and highlight the multifactorial 
interaction between environmental exposures and individual genetic predisposition, which 





2.2 COPD: Pathophysiology and Clinical Assessment 
As stated before, the hallmark feature of COPD is persistent airflow limitation.  
This is primarily attributed to a combination of the following two pathophysiological 
mechanisms: (1) small airways disease results in increased airway resistance, luminal 
obstruction, and mucus hypersecretion; and (2) permanent tissue destruction decreases 
elastic lung recoil and eliminates parenchymal tethering, which oppose airway collapse 
during exhalation [1].  These changes to the airways and parenchyma, which are 
summarized in Figure 2-2, compromise gas exchange and contribute to lung hyperinflation.  
Consequently, patients often suffer from labored breathing in relation to the severity of 
disease and are at increased risk of pulmonary illnesses, such as pneumonia, which can 
further exacerbate respiratory symptoms. 
Although individual phenotypes vary based on the relative contributions of the 
mechanisms described above, patients are clinically identified by the predominant 
presenting pathophysiology.  Clinical definitions for two of the more prevalent subtypes 
are summarized as follows [2], [26]: 
 
 
Figure 2-2.  Airflow limitation in COPD arises from changes in the airways and 




Chronic bronchitis – a chronic productive cough for three months in each of two 
successive years in a patient in whom other causes of chronic cough (e.g., bronchiectasis) 
have been excluded. 
Emphysema – a pathology term that describes structural changes associated with 
COPD, including abnormal, permanent enlargement of the airspaces distal to the terminal 
bronchioles accompanied by destruction of the airspace walls. 
Progressive tissue destruction in emphysema leads to airflow obstruction and 
subsequent lung hyperinflation as gas is trapped behind collapsed airways.  The most well-
documented mechanism for disease pathogenesis is the protease-antiprotease imbalance 
hypothesis [10], [11], which as stated earlier involves elastolytic enzymes overwhelming 
the protective effects of α1-antitrypsin resulting in excessive destruction of lung connective 
tissue.  However, the disease process is not entirely described as additional factors such as 
matrix metalloproteinases (MMPs), increased oxidant stress, cellular apoptosis, and 
mechanical forces all contribute as well [9], [11], [12], [15]. 
2.2.1 Clinical Diagnosis, Assessment, and Staging 
The cornerstone diagnostic test for airflow limitation is spirometry.  Forced 
expiratory volume in one second (FEV1) measures the amount of air that can be expelled 
from the lungs in one second following a deep inhalation, while forced vital capacity (FVC) 
measures the total volume expired.  A post-bronchodilator ratio of FEV1/FVC less than 0.7 
is indicative of airflow limitation and is used to confirm COPD diagnosis, while severity 
is classified according to the GOLD stage determined by the percent of predicted FEV1 




quality of life and include the Clinical COPD Questionnaire (CCQ), St. George's 
Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), and modified Medical 
Research Council (mMRC).  Additional tests including diffusing capacity of the lung for 
carbon monoxide (DLCO), pulse oximetry, and arterial blood gases (ABGs) provide insight 
to gas exchange in the lung, while the six-minute walk test (6MWT) is a simple 
performance-based assessment of overall lung function. 
In addition to airflow limitation severity, the GOLD system [1] is used to guide 
treatment decisions based on exacerbation risks and patient symptoms.  Four separate 
‘ABCD’ staging groups are defined based on history of exacerbations and symptom 
severity characterized by mMRC or CAT scores.  This approach, as outlined in Figure 2-3, 
addresses the limitations of FEV1 for individualized patient care and facilitates the 
formation of a treatment plan in the emergency setting that is independent of spirometric 
measurements.  Alternatively, the BODE index is another popular metric used to stratify 
risk and prognosis.  Originally proposed by Celli et al. [27] it considers body-mass index 
(B), airflow obstruction (O), dyspnea (D), and exercise capacity (E).  This multi-variable 
index is relatively simple to calculate, does not require any special equipment, and has 
better prognostic information than FEV1 alone, predicting risk of death from any cause and 
from respiratory causes.  CT-derived parameters have also been used to quantify disease 
status, most commonly low-attenuation area percent (LAA%), which characterizes the 
amount of hyperinflated tissue in the lung [17].  Newer biomechanical metrics, such as the 
Jacobian determinant, have been used to resolve disparities  between CT and spirometry 





Figure 2-3.  Assessment of COPD disease severity, modified from the GOLD 
Report 2017 [1]. 
 
2.3 End-Stage Palliative Treatments 
There is presently no cure for emphysema.  Treatments are guided by disease 
severity and are directed at alleviating symptoms and slowing disease progression.  
Management goals are to improve exercise tolerance and health status while reducing 
exacerbations and mortality [1].  While the most important intervention, regardless of 
disease severity, is smoking cessation [22], treatments can be categorized as pharmacologic 
or non-pharmacologic, the latter of which will be discussed here. 
Lung hyperinflation due to the loss of the intricate, complex structure in the lung is 




to ameliorate symptoms, improve quality of life, and lengthen survival by reducing this 
hyperinflation and partially restoring lung function.  Proposed mechanisms [29], [30] by 
which this palliative treatment improves lung function are as follows: (1) reducing 
hyperinflation better matches lung size to the thorax containing them, helping to restore 
chest wall and diaphragm mechanics; and (2) removing enlarged, emphysematous regions 
improves elastic lung recoil and radial traction on airways in more normal tissue, leading 
to improved expiratory flow rates and lung emptying.  Although the goals are identical, 
there are distinct approaches to accomplishing lung volume reduction, which are generally 
categorized as surgical and non-surgical. 
2.3.1 Lung Volume Reduction Surgery (LVRS) 
In LVRS, emphysematous tissue is typically removed by wedge excision via 
median sternotomy or video-assisted thoracoscopic surgery (Figure 2-4).  LVRS is an 
established procedure with defined indications provided by the landmark National 
Emphysema Treatment Trial (NETT) [5], [31], which demonstrated a significant survival 
advantage over medical therapy for patients with predominately upper-lobe emphysema 
and low baseline exercise capacity.  However, surgery did not confer a survival advantage 
over medical therapy when compared across all patients, despite a greater chance for 
improvement in exercise capacity.  In fact, the high-risk group actually had a reduced 
survival, limiting this approach for a number of patients.  Thus, more widespread 
implementation of LVRS is hindered by high costs, a limited number of highly experienced 





Figure 2-4.  Lung volume reduction surgery via video-assisted thoracoscopic 
surgery. 
 
2.3.2 Bronchoscopic Lung Volume Reduction (bLVR) 
Inspired by the potential benefits of lung volume reduction, however, there are 
ongoing efforts to develop less invasive therapeutic alternatives to surgery [30], [32].  This 
work has given rise to a group of techniques collectively referred to as bronchoscopic lung 
volume reduction (bLVR).  Among the more extensively investigated approaches are 
valves, sealants, and coils, which are briefly reviewed here. 
One-way endobronchial valves (EBV), are placed in the upper airways under 
bronchoscopic visualization to facilitate lobar collapse by blocking regional ventilation 
while permitting emptying of affected areas [33], [34].  Although interlobar collateral 
ventilation limits EBV treatment efficacy, the Chartis Pulmonary Assessment System can 
be used to identify intact interlobar fissures and notably improve patient selection [35].  




a method for inducing absorption atelectasis of affected emphysematous regions [36], [37].  
Here, the polymer (2% aminated polyvinyl alcohol) and cross-linker (1,5-pentanedial) 
components are mixed together and instilled in the lung to seal off airways, including 
collateral ventilation pathways which can compromise EBV efficacy.  In contrast, a more 
direct approach is the use of nitinol coils [6], [38], [39].  Nitinol, which derives its name 
from Nickel Titanium-Naval Ordnance Laboratory, is a unique material that exhibits 
temperature-dependent mechanical properties.  At room temperature, the coils are flexible 
to facilitate delivery in an elongated form through a catheter, but upon placement within 
the lung tissue, its shape-memory causes a forceful return to a predetermined configuration.  
This in effect retracts the surrounding lung parenchyma and reduces hyperinflated tissue. 
In summary, there are several bLVR techniques under clinical investigation with 
different targeted approaches to lung volume reduction.  These emerging treatments show 
promise as less invasive alternatives to surgery, although little is known regarding their 
effect on the local micromechanical lung environment.  Additional evidence is needed to 
recommend routine use beyond clinical trials, while a better understanding of the 
mechanisms determining outcomes may help direct patient-specific treatment strategies. 
 
2.4 Mechanical Forces in Emphysema 
2.4.1 CT-Inspired Computational Modeling Reveal Emphysema to be a Mechanically-
Driven Disease 
CT studies [17], [40], [41] have helped uncover the role of mechanical forces in 




Lung hyperinflation and parenchymal destruction appear on CT as areas of low tissue 
density with low attenuation [17], which characterize the extent, distribution, and 
morphology of emphysema [42].  In what is now considered a landmark study, Mishima et 
al. [17] discovered that the sizes of these low-attenuation areas, or LAA clusters, were well-
described by the power law relation: 
𝑌 = 𝐾	 ×	𝑋HI  Equation 2-1 
where 𝑌  is the cumulative number of clusters equal to or smaller than size 𝑋 , 𝐾  is 
proportional to the total number of clusters, and the exponent 𝐷 is the slope of a straight 
line fitted to the graph of 𝑙𝑜𝑔(𝑋)  versus log	(𝑌) .  Two important findings related to 
changes in the distribution exponent resulted from this study.  First, values of 𝐷 were 
statistically smaller in patients with COPD compared to controls, indicating it was a 
sensitive indicator for early emphysema.  Subsequently, 𝐷 has been used in clinical studies 
as an index of disease progression [40], [41] and to evaluate candidates for LVRS [43].  
Second, values of 𝐷 negatively correlated with LAA%.  These changes correspond to a 
decrease in the slope of 𝑙𝑜𝑔(𝑋) versus log	(𝑌) as disease severity worsened, reflecting 
fewer clusters but with larger sizes on average.  To elucidate a potential mechanism 
explaining these changes, a computational elastic spring network was generated to model 
a section of lung tissue [17].  The authors demonstrated that selectively breaking springs 
carrying the highest forces to simulate progressive tissue failure yielded distributions of 
cluster sizes that matched those observed on CT.  As a result, this work established the 
hypothesis that emphysema progressed via mechanical rupture of alveolar walls, leading 




this view, demonstrating that emphysematous patterns of tissue breakdown could not be 
reproduced solely by chemical processes or random cutting, while other computational 
work [45] reported similar observations when extending the elastic network model from 
two to three dimensions. 
2.4.2 Experimental Evidence Confirm Model Predictions 
Small animal models of emphysema also support a force-driven mechanism of 
progression.  Previous work [14] demonstrated alveolar wall rupture in elastase-treated 
slices of rat lung tissue as a direct result of local mechanical forces.  It was also shown that 
increases in lung compliance in mice paralleled changes in airspace heterogeneity 
associated with force-induced failure of the extracellular matrix (ECM) [44].  Nevertheless, 
inflammatory processes, concerted action of proteases, and ECM remodeling are also 
known to contribute.  It has been suggested [15] that these two processes function more 
broadly within self-propagating dynamic loops of enzymatically initiated but mechanically 
driven tissue destruction.  In this scenario, pro-inflammatory processes might be amplified 
and directed by the local distribution of forces in the tissue, a phenomenon known as 
mechanotransduction [9], [46].  A schematic describing these dynamic feedback loops is 
shown in Figure 2-5.  Thus, while our understanding of emphysema progression (and more 
importantly how it can be modified or reversed) is far from complete, convincing evidence 
in the form of CT, computational, and animal data suggest that the concept of force-







Figure 2-5.  Schematic describing the complexity of multi-scale 
mechanotransduction feedback mechanisms influencing ECM composition and 






2.5 Animal Models 
Various animal models have been developed in an effort to recreate the 
pathophysiology observed in COPD.  These models vary in the method used to initiate 
disease and have been applied across a number of species including small animals such as 
mice [47]–[49], rats [50]–[53], and rabbits [54] as well as large animals such as dogs, 
sheep, monkeys, and pigs [55]–[57].  Although no model can perfectly capture all of the 
pathophysiologic changes observed in humans, they provide useful insight to disease 
processes and aid in identifying potential treatments. 
2.5.1 Elastase-Induced Model 
Exogenous administration of elastase enzyme, simulating the protease-antiprotease 
imbalance associated with emphysema, is one of the most widely used disease models [14], 
[44], [47], [49], [50].  In elastase-induced emphysema, the heightened proteolytic activity 
leads to destruction of lung tissue and enlargement of airspaces.  This model is favorable 
for its quick and economic establishment, while the severity of disease can be modified 
according to enzyme dose; however, there are drawbacks.  Often porcine pancreatic 
elastase (PPE) is used as a less expensive substitution for human neutrophil elastase (HNE), 
despite having separate primary endogenous inhibitors, α2-macroglobulin and α1-
antitrypsin, respectively [58].  More importantly though, a reductionist approach involving 
elastase digestion alone does not incorporate the additional inflammatory and enzymatic 
mediators that contribute to disease progression [58].  Therefore, while elastase instillation 
rapidly generates characteristic functional and structural emphysematous changes, its 




2.5.2 Cigarette Smoke-Induced Model 
In comparison, cigarette smoke-induced models that directly expose animals to 
smoke better represent human pathophysiology [59].  For smoke-induced emphysema, 
animals are exposed to cigarette smoke via nose-only (mainstream) or whole-body (side 
stream) administration systems.  To standardize measurements between laboratories, 
specific research cigarettes have been made readily available for investigators, such as the 
Kentucky 2R4F/2R5F, though name-brand cigarettes are also used [59].  Physiologic 
measurements, such as serum cotinine (a metabolite of nicotine) and blood 
carboxyhemoglobin (COHb), and smoking conditions, including total suspended particles 
(TSP) and total particular matter (TPM), are also provided in some cases.  Nevertheless, 
reported dosing (i.e., number of cigarettes, filtering, duration of smoking) varies between 
studies [59].  Han.  Despite inter-model variability, the smoke-induced model is considered 
a superior model for COPD, inciting disease through similar exposure as in humans, with 
components of both small airway disease and emphysematous destruction [58].  The 
primary drawback, however, is the time and effort required to establish this model, 
especially in rodents which can take up to 6 months to observe clinically significant 
changes [58], [59].  For comparison, only a few weeks are typically required with elastase 
[49], [50].  In addition, disease severity with smoke exposure can be mild, regardless of 
the amount or duration of smoking.  It is estimated that changes observed in mice are only 




2.5.3 Cigarette Smoke Extract (CSE)-Induced Model 
As an alternative to direct cigarette smoke exposure, chemical-containing solutions 
of cigarette smoke extract (CSE) can also be used as a disease model.  To generate the 
solution, a cigarette is combusted and the gas phase is drawn through an aqueous buffer 
trapping the functional chemical compounds in the suspension [60], [61].  This preparation 
has the benefit of being added directly to cells in vitro [62] [63] or to animals in vivo via 
intraperitoneal (i.p.) injection or tracheal instillation [51], [52], [64]–[67].  CSE is 
commonly used in mice, with one head-to-head study demonstrating comparable changes 
in histology, lung function, and inflammatory markers between i.p. injection and traditional 
smoke exposure [68].  The incubation period for this method is also shorter.  CSE models 
evaluating the efficacy of pharmacologic interventions have reported alveolar enlargement, 
parenchymal destruction, and changes in antioxidant activity within only a few weeks in 
rats [51], [52], [66], [67].  A systematic review found similar changes between CSE models 
in mice and rats, which exhibited aspects of COPD that were comparable to disease in 
humans [69].  Although additional studies are needed to confirm these findings, the CSE-
induced model has greater flexibility and benefits from invoking disease via similar 
pathways as the smoke-induced model, but in a shorter time-frame. 
2.5.4 Other Models 
In addition to those discussed here, there are several other animal models of 
emphysema.  These include but are not limited to apoptosis and starvation-induced models 
[58]; injurious mechanical ventilation [49]; lipopolysaccharide (LPS) instillation, which 




methods [49], [70]; and genetically modified animals [57].  Although each model carries 
its own unique benefits, limitations, and indications, the most commonly used and broadly-
applicable models are summarized above. 
 
2.6 Precision Cut Lung Slices (PCLSs) 
The PCLS has emerged as a robust tool for investigating structure-function 
relations in the lung ex vivo [71].  As the name implies, PCLSs are generated using a 
precision tissue slicing instrument, such as a vibratome [72], to finely divide the lung into 
several horizontal or vertical segments with thicknesses typically on the order of hundreds 
of microns.  Since the lungs are relatively soft and will collapse in the absence of the 
negative distending pressure of the intrapleural space, it is necessary to inflate the lungs 
with a soft gel, such as low-melt agarose, to maintain lung rigidity throughout slicing [71].  
Although most applications use the slices shortly after preparation [73], PCLSs can be 
cryopreserved to minimize the number of animals needed, while largely preserving 
viability and function [74], [75].   
The primary benefit of the PCLS is that the native extracellular environment is 
maintained so that functional relationships among the airways, parenchyma, and resident 
cells therein are preserved [71].  This facilitates direct observation and manipulation of 
intact airways and cells, especially in otherwise inaccessible deep regions of the lung, 
providing an ex vivo model to recapitulate in vivo exposure to toxic substances [73], [75], 
[76] and pharmacologic therapy [77]–[80].  This technique is well-suited to explore airway-




enzymatically-digested lung slices highlight the relevance of the PCLS for studying 
structure-function changes in emphysema [84].  Although initially developed as a platform 
for assessing pharmaceutical effectiveness [85], PCLSs have also been used for cyclic 
stretching experiments to mimic the dynamic conditions experienced during tidal breathing 
[86]–[89].  The PCLS represents an intermediate between previous methods that either 
stretched cells adhered to a flexible membrane [90]–[93] or measured changes in 
macroscopic mechanical properties of tissue strips stretched uniaxially [94]; however, this 
approach offers better microscopic resolution with preserved lung structure, which can 
influence cellular responses to stretch and chemical exposure. 
There have been several different methods used to stretch PCLS, mainly 
distinguished by the manner in which the slices are attached to an underlying flexible 
substrate.  In one design, the lung slice is clamped to a polydimethylsiloxane (PDMS) 
membrane while a distending pressure is applied from below to non-uniformly deform the 
membrane [86].  In another design, PCLSs are individually stitched to a stretchable silicone 
membrane using silk sutures [88], [89].  This approach has demonstrated repeatable 
uniform stretch of lung slices but can be time consuming and have relatively high failure 
rates.  In contrast, an alternative technique relies on a hollow cylindrical indenter to 
compress a layer of polyacrylamide gel causing it to deform and subsequently stretch a 
lung slice secured between the gel and indenter [87].  This device can be used to apply 
tidal-like breathing strains to individual airways with real-time imaging of dilation and 
contraction; however, this approach imposes a relatively small area-of-stretch and limited 




depends on the target application as well as the experience and preference of a particular 
research group. 
Previous studies in stretched lung slices, as detailed above, have primarily focused 
on ventilator-induced lung injury (VILI) [88], [95] or changes in airway mechanics [87].  
Despite the demonstrated feasibility of this approach, however, such techniques have yet 
to be adopted for COPD, leading to a paucity of data describing mechanotransduction-
mediated effects on disease pathogenesis and progression.  Consequently, cyclic stretching 
of PCLSs has substantial potential to uncover new insight to these underlying disease 
mechanisms, providing direct exposure to exogenous substances under conditions similar 




CHAPTER 3– Computational Modeling of Lung Volume Reduction 
Findings from this work were published in PLoS Computational Biology as an original 
research article entitled “Predicting Structure-Function Relations and Survival Following 
Surgical and Bronchoscopic Lung Volume Reduction Treatment of Emphysema” [96]. 
 
3.1 Introduction 
Emphysema, a subtype of chronic obstructive pulmonary disease (COPD), is a 
progressively destructive lung tissue disease characterized by abnormal and permanent 
enlargement of airspaces distal to the terminal bronchioles.  This largely preventable, yet 
presently incurable disease is associated with high morbidity and mortality, presenting a 
substantial burden on resource utilization [1], [97].  While pharmacological treatment can 
have limited benefits for patients, especially in advanced stages of disease, surgical and 
bronchoscopic treatments aimed at reducing hyperinflated lung volumes have been shown 
to ameliorate symptoms of dyspnea, improve quality of life, and in certain cases provide a 
survival advantage [5], [6], [98]. 
Proposed mechanisms by which lung volume reduction results in functional 
improvements primarily involve a reduction in hyperinflation leading to restored chest wall 
and diaphragm mechanics, and an increase in elastic lung recoil (hence a decrease in lung 
compliance) and radial traction on airways leading to improved expiratory flow rates and 
lung emptying [29], [30].  In lung volume reduction surgery (LVRS), emphysematous 
tissue is removed from the upper lung by wedge excision typically via median sternotomy 




with predominantly upper-lobe emphysema and low baseline exercise capacity [31], many 
still do not meet the strict indications for this procedure.  Moreover, widespread 
implementation of LVRS is hindered by high costs, a limited number of highly experienced 
centers, and significant post-procedural morbidity and mortality [30]. 
Recently, a growing number of non-surgical techniques have been developed with 
the goal of providing less invasive alternatives [32].  Among the more extensively 
investigated of these bronchoscopic lung volume reduction (bLVR) treatments are (1) 
nitinol coils, which return to a predetermined shape after placement in target airways while 
retracting the surrounding diseased lung parenchyma [6], [38], [39]; (2) one-way valves, 
which facilitate lobar collapse by blocking regional ventilation but permitting emptying of 
affected areas [33]–[35]; and (3) biomaterial-based lung sealants, which function to block 
small airways and prevent collateral ventilation pathways inducing absorption atelectasis 
in the delivered region [36], [37], [99].  While recent evidence appears to be trending in 
support of bLVR and ongoing studies are expected to further define optimal 
implementations for such approaches [30], the immediate and long-term effects in the lung 
have yet to be fully understood. 
Previous work has focused primarily on the benefits in clinical function and 
survival outcomes for these treatments and thus, provides no insight into the 
micromechanical origins leading to such improvements.  The aim of this study was to 
investigate the structure-function relationships before and after lung volume reduction 
using a computational elastic network model [13], [15], [17], [100].  Here, we simulate 




changes in network compliance and structure following LVRS and bLVR interventions.  
Our simulations shed light on the factors contributing to immediate and long-term 
treatment efficacy as well as predicted outcomes spanning several years.  We show that 
macroscopic improvements in compliance following lung volume reduction are correlated 
with the microscopic distribution of mechanical forces in the local lung environment.  
Furthermore, our model predicts similar survival and quality of life benefits for both 
interventions, indicating how bLVR may be implemented as an effective, less invasive 
treatment for advanced emphysema. 
 
3.2 Results 
3.2.1 Network Modeling of Emphysema Progression 
The elastic behavior of lung tissue was modeled using a two-dimensional (2D) 
computational network of linearly elastic elements arranged in a hexagonal lattice under 
the influence of gravity.  Disease progression was driven by elimination of network 
elements carrying a high force, representing in vivo tissue failure in regions of high local 
mechanical stress.  Figure 3-1A shows a representative simulation beginning with healthy 
tissue followed by gradual deterioration.  As tissue failure progressed (i.e., high force 
elements were removed), smaller airspaces were observed to coalesce into larger 
neighboring airspaces representing the process of airspace enlargement characteristic of 
emphysema progression.  Figure 3-1B illustrates the two lung volume reduction techniques 
initiated in parallel from the same network configuration.  LVRS was simulated by 




specific affected regions of the network. 
To characterize functional changes within the network at each configuration, the 
network compliance, C was calculated as the inverse of the 2D bulk modulus.  To 
characterize structural changes, network heterogeneity was quantified as the coefficient of 
variation of individual airspace sizes, CVarea.  Prior to lung volume reduction, values of C 
and CVarea increased from baseline consistent with the loss of elastic recoil and enlarged 
airspaces observed in emphysema (Figure 3-1C).  In the representative network shown, 
both the non-specific LVRS and the region-specific bLVR yielded comparable immediate 
and long-term improvements in network elasticity as characterized by similar reductions 
and recoveries in C, respectively.  In contrast, upper network resection with LVRS was 
less effective in other networks as characterized by differences in reduction and recovery 
in C (Figure 3-2).  Thus, variability in initial conditions among the N=14 large networks, 
representing inter-subject variability, simulated disease distributions with treatment-
specific responses to lung volume reduction. 
3.2.2 Immediate Response to Lung Volume Reduction 
To distinguish networks demonstrating a benefit from LVRS, we defined the 
predictive index β characterizing network heterogeneity below the line of LVRS resection.  
Here, β was calculated as the coefficient of variation of airspace sizes below the line of 
LVRS resection.  Less heterogeneity in this lower region (i.e., smaller β) corresponded to 
relatively spared tissue due to predominately upper lung emphysema.  More heterogeneity 
in this region (i.e., larger β) corresponded to emphysematous tissue destruction extending 




defined to divide the networks into LVRS responder (N=8) and marginal-responder (N=6) 
groups.  As shown in Figure 3-3A, the immediate drop in C following LVRS was inversely 
related to β (R2=0.600), with larger changes observed for responders compared to marginal-
responders (36.4±8.6% vs. 20.1±4.4%; p=0.001).  Representative networks for both groups 
are shown in Figure 3-4, where β is inversely related to the overall network heterogeneity 
quantified by CVarea.  That is to say, smaller values of β implied heterogeneous network 
structure amenable to LVRS, whereas larger values of β implied homogeneous disease 
patterns less effectively treated by resection of the upper network. 
To better characterize the mechanical differences between networks with different 
β values, we compared the distribution of forces carried by individual network elements 
before and after intervention.  As shown in Figure 3-3B, LVRS skewed the distribution to 
the right (i.e., toward larger forces) for responders, whereas it did not significantly alter the 
skewness relative to before intervention for marginal-responders.  Interestingly, bLVR 
skewed the distribution of forces to the right for all networks and reduction conditions.  As 
shown in Figure 3-3C, plotting values of C after bLVR against the coefficient of variation 
of forces (CVforce) revealed that a simple power law function fitted the data well: 
𝐶~CVSTU>VHW.Y  (R2=0.816).  This observation demonstrates that macroscopic functional 
changes immediately after bLVR are linked to the underlying microscopic force 
redistribution.  Taken together, these findings suggest that the introduction of high-force 
elements plays a critical role in lung volume reduction efficacy and is dependent on pre-




3.2.3 Long-term Progressive Changes in Structure and Function 
In addition to the immediate response following lung volume reduction, we also 
evaluated the long-term response for both LVRS and bLVR.  Disease progression was 
modeled as consecutive stages of increasing network deterioration characterized by the 
cumulative number of broken elements at each stage.  Figure 3-5 shows the average 
changes in C and CVarea before and after intervention. 
Prior to lung volume reduction, average values of C and CVarea increased with 
worsening disease severity consistent with a softening network and expanding 
emphysematous regions.  Comparing networks classified as either responders or marginal-
responders, statistically significant differences between groups were detected for C and 
CVarea just before intervention, suggesting that responders were slightly less elastic with 
more heterogeneous disease progression.  Following LVRS, average values of C and CVarea 
initially returned to near baseline levels.  Responders demonstrated smaller increases in C 
and CVarea at advanced disease stages indicating more sustainable functional and structural 
improvements compared with marginal-responders.  This highlights the improved long-
term treatment efficacy in networks with smaller vs. larger β, given similar stages of tissue 
deterioration prior to intervention.  Following bLVR, no differences were detected between 
networks classified as either responders or marginal-responders.  Instead, long-term 
response was related to bLVR reduction size.  Networks with affected regions reduced to 
20% of their original size yielded smaller increases in C at each stage of disease progression 
compared with those reduced to 40%, while average values of CVarea were not statistically 




3.2.4 Predicted Outcomes of Survival and Quality of Life 
Based on the long-term simulations in this computational model, we compared the 
predicted outcomes for LVRS and bLVR as influenced by lung compliance.  We found 
that all treatments actually accelerated network deterioration, more than doubling the rate 
of increase in C prior to intervention (Figure 3-6A).  Despite the accelerated rate of 
increase, treatments restoring C to near baseline levels lengthened the expected survival 
estimated as the number of broken elements required to reach a 60% increase from 
baseline.  LVRS and bLVR reduction to 20% yielded increases of 1.51±0.13 and 1.51±0.11 
times longer than without treatment, respectively (Figure 3-6B).  We also calculated a 
combined index related to the area enclosed by the threshold and the curve defined by 
values of C (schematic shown in Figure 3-7).  By incorporating both the rate of increase 
and the number of broken elements, this index termed “Relative Benefit” represented a 
measure for quality of life.  LVRS and bLVR reduction to 20% yielded similar increases 
of 11.7±3.7 and 10.6±3.2 relative to without treatment, respectively, while bLVR reduction 
to 40% yielded a considerably smaller increase of 4.7±1.8 (Figure 3-6C).  These model 
predictions indicate that bLVR can yield similar outcomes as LVRS when affected regions 
are appropriately reduced in size. 
 
3.3 Discussion 
Lung volume reduction represents the primary therapeutic strategy for advanced 
emphysema.  LVRS is a well-established surgical treatment but is limited by strict 




approaches are on the rise providing less invasive alternatives with the potential for 
considerably lower post-procedural morbidity and mortality.  While previous work has 
evaluated improvements in clinical function and survival advantage provided by these 
techniques, little is known about the corresponding micromechanical mechanisms 
responsible for improvement in survival and quality of life.  In this study, we constructed 
2D elastic networks to simulate lung volume reduction with LVRS and bLVR in a force-
based model of emphysema progression.  Our main findings include: (1) analysis of 
network structure using a simple measure of disease heterogeneity prior to lung volume 
reduction can predict LVRS efficacy; (2) macroscopic functional improvements following 
bLVR correspond to microscopic changes in force heterogeneity; and (3) lung volume 
reduction improves aspects of the predicted survival and quality of life influenced by 
contributions of lung compliance, albeit while accelerating disease progression. 
Mechanical forces have long been suggested to play a role in emphysema 
progression [101].  Previous work [14] provided early evidence demonstrating alveolar 
wall rupture in elastase-treated tissue slices as a direct result of local mechanical forces.  
Subsequently, it was shown that increases in lung compliance paralleled changes in 
airspace heterogeneity associated with force-induced failure of the extracellular matrix 
(ECM) [44].  Inflammatory processes, concerted action of proteases, and ECM remodeling 
also likely contribute to emphysema progression [102]–[105]; however, their role has been 
proposed more broadly within self-propagating dynamic loops of enzymatically initiated 
but mechanically driven tissue destruction [15].  Previous network model simulations have 




chemical process, such that the inclusion of local forces are critical in developing observed 
emphysema patterns [15], [17].  Alternative models based on uniform softening or random 
cutting have also been found to poorly characterize these progressive changes [44].  Thus, 
we consider the network model described here to provide a suitable description of 
emphysema progression with the capacity for studying the structure-function relations 
following lung volume reduction. 
It is known that patients with predominately upper-lung emphysema have more 
favorable outcomes following LVRS [5], [31].  In this study, greater improvements in C 
after LVRS were observed in those with less affected lower network regions (Figure 3-3A) 
as resection of the upper diseased airspaces allowed for the remaining tissue to restore 
function.  These networks also displayed smaller increases in C, especially at advanced 
disease stages (Figure 3-5A), as well as considerably smaller decreases in total network 
stress, σ, that may reflect transpulmonary pressure in the lung (Figure 3-8).  This is 
consistent with previous experimental data demonstrating that improvements after LVRS 
are correlated with increased ratios between upper to lower zone emphysema (determined 
by computed tomography, CT), but are not well predicted by pre-surgical measurements 
of static lung compliance or elastic recoil [106], [107].  The observed improvements in C 
may also be related to differences in force distribution between LVRS groups (Figure 
3-3B).  One possible explanation is that emphysematous areas remaining after LVRS act 
as “shock-absorbers” contributing to a softer overall tissue, whereas networks with 
relatively low structural heterogeneity better facilitate force propagation and a stiffer 




characterize the distribution of forces before and after intervention (Figure 3-9).   The tail 
of the distribution varied with the specific intervention and may indicate the emergence of 
complex network behavior [108], which would be a unique case when increased lung 
heterogeneity potentially contributes positively to treatment outcome.  Nonetheless, these 
findings suggest a mechanism that may explain how functional changes evolve based on 
intrinsic structural differences prior to LVRS. 
Motivated by the benefits observed with LVRS, however, non-surgical 
bronchoscopic alternatives have been the focus of recent investigations, where patient 
outcomes have improved as bLVR techniques have become more proficient [30], [32].  A 
recent study using endobronchial valves [39] reported that improvements in measured 
FEV1 were correlated with effective collapse of the affected lobe, a finding confirmed to 
be enhanced by fissure completeness and absence of interlobar collateral ventilation [35].  
This is conceptually similar to our model predictions that bLVR reduction size is inversely 
related to immediate and long-term improvements in C (Figure 3-3 and Figure 3-5).  
Comparing bLVR for multiple reduction sizes revealed that macroscopic functional 
improvements in C were linked to underlying microscopic changes in force heterogeneity.  
Although radiographic evidence indicates near complete reduction is currently not 
achievable [30], [36], [39], our findings highlight important structure-function interactions 
between network reorganization after bLVR and its effect on the local mechanical 
environment in the lung (observations which would otherwise be impossible to detect via 
imaging or functional studies).  This unexpected relationship demonstrates that bLVR can 




which elevated forces in close proximity to reduced areas may promote local tissue 
destruction. 
By simulating LVRS and bLVR in parallel from the same configuration, we were 
able to directly contrast outcomes and disease progression after treatment.  In general, lung 
volume reduction led to more rapid tissue failure as a result of increased mechanical forces 
on elastic elements.  This is consistent with clinical reports of accelerated deterioration of 
lung function (relative to pre-surgery) observed in patients following LVRS [109], [110].  
Despite elevated rates of tissue failure, LVRS and bLVR are predicted to lengthen survival 
and improve quality of life by restoring lung function to levels closer to healthy tissue 
(Figure 3-6).  Statistically comparable outcomes were observed for LVRS and bLVR 
reduction to 20%, suggesting that bLVR is capable of similar treatment efficacy as current 
surgical standards.  The modality-specific reduction in bLVR efficacy highlighted by 
Ingenito et al. [32] might also be explained by the less proficient treatment modeled by 
bLVR reduction to 40%.  Nonetheless, these computational findings support bLVR 
application across an even broader population, as suggested by Deslee et al. [111], and 
could serve as a bridge treatment to delay lung transplantation [112].  This is of particular 
interest given the potential for substantially less invasive bronchoscopic techniques to 
extend treatment options to those who do not qualify for LVRS.   
Changes in relative lung volumes are also correlated with treatment efficacy.  
Fessler et al. [29] have shown that decreases in residual volume (RV) relative to total lung 
capacity (TLC) contribute to improvements in FEV1 after LVRS.  Our results support these 




regions represent treatments that come closest to the removal of pure RV and allow for 
expansion of more normal regions.  Interestingly, related studies evaluating the success of 
bilateral lung transplant somewhat counterintuitively observed significantly better 
outcomes in cases with donor lungs larger than the recipient thorax (as estimated by the 
donor-recipient predicted TLC ratio) [113], [114].  It was proposed, however, that a 
decrease in lung compliance post-transplant was likely a contributing factor for survival 
and performance, which would agree with the benefits of lung volume reduction modeled 
here.  The importance of these anatomic considerations also suggests the potential for 
coupling this computational approach with CT imaging in the future.  The non-invasiveness 
of such an analysis would be uniquely suited to infer patient outcomes prior to treatment 
and aid clinical decision-making. 
There are several limitations of the network model that must be considered when 
associating computational findings with clinical outcomes.  (1) Our model considers the 
lung tissue to be a collection of interconnected acinar compartments; however, recent work 
has highlighted the involvement of the small airways in COPD development.  Narrowing 
and loss of terminal bronchioles are believed to increase small airway resistance in COPD 
patients [115] and may even precede emphysema development [116].  Hiorns et al. [82] 
have further demonstrated the dynamic and spatially heterogeneous nature of these airway-
parenchyma tethering interactions in precision cut lung slices.  Although interactions at 
this scale are not included here, the stiffer airways would likely be associated with local 
parenchymal destruction.  The hexagonal network units might alternatively reflect the 




lobules and enlarged lesions characteristic of emphysema, as described by Hogg et al. 
[117].  (2) The number of broken elements may not have a direct temporal correlation with 
progression in vivo even though tissue destruction is clearly associated with more 
developed disease severity.  Moreover, emphysema progression is modeled by breaking a 
specified number of elements at each stage of disease.  An alternative approach would be 
to define a global threshold, as investigated for ventilator-induced lung damage [118], 
above which elements are considered to fail.  Both approaches yield similar disease 
patterns but could influence the apparent rate of tissue failure differently.  Nonetheless, 
observed inter- and intra-subject variability in vivo, along with only few data from follow-
up studies, validate the general interpretations of our results presented here.  (3) Ventilatory 
dependencies associated with incomplete lung fissures are not captured by our network 
models; however, the bLVR simulations presented here are markedly similar to the 
mechanical action of nitinol coils and biomaterial-based lung sealants believed to function 
independently of collateral ventilation pathways [36], [39].  (4) Chest wall mechanics, 
irregular lung boundaries, nonlinear dynamics, 3D interactions, enzyme kinetics, and ECM 
remodeling were also not included in this study but could improve the interpretation of 
factors contributing to disease progression.  Future work expanding bLVR in a true 
multiscale model of emphysema in 3D [45] that incorporates airway-parenchymal 
interactions, inflammation, and enzyme kinetics may provide additional insights and 
enhance the potential for clinical application.  Despite these limitations our network model 
has been shown to generate disease patterns with strong correlation to those observed using 




emphysema progression [15]. 
While these computational simulations represent a simplified view of emphysema 
progression, this model provides new perspective into the structure-function relations 
underlying the progressive nature of emphysema before and after lung volume reduction.  
Immediate and long-term responses to these interventions appear to be intimately linked to 
changes in microscopic force heterogeneity within the lung, which could explain known 
structural limitations for surgical approaches and emphasize pertinent implications in 
disease progression for bronchoscopic approaches.  Furthermore, our findings suggest that 
effective bronchoscopic reduction of affected lung tissue can achieve similar if not better 
functional improvements, survival advantages, and quality of life benefits as currently 
established surgical techniques.  These insights have the potential to inform more 




3.4.1 Experimental Design 
We constructed N=14 networks to model the elastic behavior of the lung 
parenchyma with different initial conditions simulating inter-subject variability.  Networks 
were progressively degraded by eliminating elements carrying the highest forces and then 
finding the network configuration with minimal elastic energy for five sequential iterations.  
LVRS and bLVR were then applied to the same network configuration and the treated 




tracked for each network configuration to characterize changes at each stage of disease 
progression.  Finally, predicted survival and quality of life outcomes were compared for 
both treatments. 
3.4.2 Elastic Network Model 
The 2D network model used in this study has been described previously [13], [15], 
[17], [100], [119].  Briefly, elastic elements inter-connected via pin joints were allowed to 
rotate freely while nodes bordering the perimeter of the network were kept fixed to ensure 
the network was initially pre-stressed and hexagonal units, representing individual acini, 
were not collapsed.  For each configuration, the total elastic energy, Etot was calculated as 






 Equation 3-1 
where ki are the linear spring constants and Δli are the individual element displacements 
from their resting length.  Each network consisted of 6,987 elastic elements and 2,310 
hexagonal cells (85x56 nodes).  Uniform distributions (Mean ± SD) of spring constants 
(1.0 ± 0.4) and resting lengths (0.5 ± 0.1) were assigned to the elastic elements to introduce 
a degree of initial heterogeneity. 
The minimum energy corresponding to the equilibrium configuration of the 
network was obtained using Equation 3-1 with a variant of the simulated annealing 
technique [120], [121].  Here, the position of each node was displaced by a small amount 
proportional to and in the direction of the local resulting force on the node.  If the change 




configuration representing a lower energy state of the system was accepted.  Alternatively, 
for ΔE ≥ 0, the new configuration could be accepted with probability 𝑃 = 𝑒𝑥𝑝(−∆𝐸 𝑇⁄ ) 
where T was a control parameter that was sequentially reduced until a pre-defined 
convergence criterion was reached. 
Gravity dependence in the network was simulated by applying additional 
downward forces at each node with magnitude proportional to the number of dependent 
nodes below.  This relatively weak influence represented the net effect of gravity over long 
time-scales proposed to enhance tissue destruction in the upper lung [101].  In the absence 
of this term, emphysema would be expected to progress with equal probability in any 
region of the network. 
3.4.3 Force-Based Emphysema Progression and Lung Volume Reduction 
Emphysema was initiated in the network model by randomly breaking ~4% of all 
the elastic elements.  Tissue failure was then simulated using a force-based destruction 
approach.  Elastic elements were sorted by their corresponding force, and the top 0.7% of 
elements were broken with probability P=0.40.  Individual elements were not considered 
to experience fatigue behavior.  The modified network was solved to yield a new 
configuration and distribution of forces, which corresponded to a later disease stage with 
different elastic elements at risk for failure.  This discretized approach generated a disease 
progression driven by the spatial distribution of forces while the probabilistic elimination 
of elements introduced a degree of stochasticity to each network, limiting the deterministic 
nature of each simulation.  These steps were repeated for a total of five iterations simulating 




LVRS and bLVR were applied in parallel to reduce affected emphysematous 
regions.  To simulate lung resection in LVRS, the upper 30% of the network was removed 
and affected regions intersected by the threshold were stretched to form a continuous, fixed 
horizontal upper border.  To simulate reduction of enlarged airspaces in bLVR, nodes 
encompassed by a selected perimeter, corresponding to the region to be reduced, were 
moved toward their geometric center of mass.  Regions including a fixed border were 
asymmetrically reduced in size parallel to the axis of the border.  For each network, affected 
regions were selected and then reduced to 1, 20, or 40% of their original size. 
3.4.4 Estimation of Functional and Structural Network Parameters 
Mechanical stress σ was calculated for each network configuration by numerically 
differentiating the total energy, Etot of the system at the equilibrium configuration and after 
stretching the network by a small bi-axial strain, ε = ±0.01.  Here, the equilibrium 
configuration was assumed to correspond to FRC, representing a static measurement of 
lung function.  Networks were then stretched with a sinusoid of amplitude ε = ±0.04 around 
the equilibrium configuration, such that the 2D bulk modulus was defined as the slope of 
the corresponding stress-strain curve.  The compliance C was calculated as the inverse of 
the estimated network bulk modulus at each stage of disease progression.  To facilitate 
comparisons with baseline, σ and C are reported as percent changes from the initial network 
configuration prior to emphysema destruction. 
Network structure was quantified by considering the sizes of individual airspace 
units.  Each network configuration was converted to a binary image and the number of 




Overall structural heterogeneity was then assessed as the coefficient of variation of airspace 
sizes, CVarea.  For network configurations directly before intervention, we also considered 
the coefficient of variation for airspaces below the line of LVRS resection.  This predictive 
index, referred to as β, subsequently characterized disease heterogeneity in the network not 
resected by LVRS.  Note that β was calculated as a single predictive index before treatment, 
whereas CVarea was calculated for each stage of disease progression to track changes in 
overall network structure. 
3.4.5 LVRS and bLVR Outcome Predictions 
The rate of tissue failure was estimated before and after intervention as the increase 
in C over four stages of disease progression.  The number of broken springs required to 
reach a 60% increase in C was calculated for each network as an estimate of survival.  
However, since network deterioration prior to treatment was typically less than this 
threshold a second order polynomial was fitted to values of C to estimate survival in the 
absence of any lung volume reduction.  The relative benefit of treatment was then 
calculated as shown in the schematic (Figure 3-7).  The area between the survival threshold 
and the compliance curve represents a composite index for quality of life, incorporating 
both the rate and sub-threshold duration of disease progression.  Larger values of this area 
correspond to lower values of C over a longer period of time and hence represent better 
quality of life.  To compare the benefits provided by lung volume reduction, data are 





Network simulations were completed using custom-developed software, which has 
been utilized previously to generate and analyze networks in conjunction with other 
experimental studies [13], [15], [17], [100], [119].  Network manipulations involving 
LVRS and bLVR were implemented cooperatively with this program using original scripts 
developed in MATLAB (MATLAB r2013a, MathWorks, Natick, MA). 
3.4.7 Data Analysis 
 Two-way repeated measure analysis of variance (ANOVA) was used to compare 
network values of C, CVarea, and σ between treatment groups at each stage of disease 
progression, as well as the skewness of force distributions for each treatment group.  One-
way ANOVA was used to compare estimates of disease progression rate, survival, and 
relative benefit.  Post-hoc Holm-Sidak and Tukey tests were used to determine differences 
between groups.  The average change in C after LVRS for responder and marginal-
responders were compared using a t-test.  For all comparisons, p<0.05 was considered 
significant.  Statistical analyses were performed using SigmaPlot (SigmaPlot v12.3, Systat 







Figure 3-1.  Network Model of Lung Volume Reduction.  (A) Representative simulation of 
emphysema progression before intervention, and (B) comparison of lung volume reduction 
techniques in a responder network.  (i) Initial network configuration representing healthy tissue, 
direction of gravity indicated by arrow.  (ii) Disease progression initiated by randomly breaking 
~4% of elements.  (iii-v) Gradual network destruction representing tissue failure during emphysema 
progression.  (vi) Illustrations of lung volume reduction techniques initiated from the same disease 
condition.  For LVRS, the upper 30% of the network (red shaded region) was removed and 
intersected regions were stretched (red arrows) to form a continuous upper border (solid line).  For 
bLVR, affected regions (red shaded areas) were reduced (black arrows) to 20% of their original 
sizes.  (vii-x) Disease progression following either LVRS or bLVR, with reduced regions shown 
(grey shaded areas).  Color bar represents strain distribution of individual elements.  (C) Changes 






Figure 3-2.  Lung Volume Reduction in a Marginal-responder Network.  (A) Representative 
simulation of emphysema progression before intervention, and (B) comparison of lung volume 
reduction techniques in a marginal-responder network.  See Figure 3-1 for additional details on 







Figure 3-3.  Immediate Response to Lung Volume Reduction.  (A) Networks with lower values of 
β (LVRS responders, dark blue) demonstrated larger changes in compliance, C compared to 
networks with higher values of β (LVRS marginal-responders, grey).  (B) Skewness of force 
distributions before and after lung volume reduction.  Error bars represent standard error and 
*indicates statistically larger compared to before intervention as well as LVRS marginal-
responders.  (C) Relationship between C and the heterogeneity in force distribution, CVforce after 
bLVR reduction to 1% (dark grey), 20% (green), and 40% (open circles) of their original size.  A 
power law, equivalent to a straight line on a log-log graph, fitted the data well with exponent of -







Figure 3-4.  Structural Heterogeneity in LVRS Networks.  (A) Representative responder (left) and 
marginal-responder (right) configurations prior to LVRS.  Tissue heterogeneity below the line of 
resection was characterized by the predictive index β (see definition in the main text), while CVarea 
represented heterogeneity throughout the entire network.  Blue shading indicates larger, affected 
regions not removed by LVRS (shaded upper region).  (B) Prior to LVRS, responders were 
characterized by greater overall heterogeneity (i.e., larger CVarea; p = 0.036) limited to the upper 






Figure 3-5.  Long-term Progressive Changes in Structure and Function.  Network parameters for 
emphysema progression before intervention (left) and then following LVRS (center) and bLVR 
(right).  Mean values are shown for (A) increases in compliance, C; and (B) the coefficient of 
variation for airspace size.  Disease progression was characterized by the cumulative number of 
broken elements and shown as a percentage of the total number of elements in the network, error 
bars represent standard deviation.  Networks were divided before treatment (squares) and after 
LVRS (triangles) to illustrate differences between LVRS responders (N=8, dark blue) and 
marginal-responders (N=6, grey).  All networks (N=14) shown for bLVR reduction to 20% (green 






Figure 3-6.  Outcome Predictions Following Lung Volume Reduction.  (A) Lung 
volume reduction accelerated the rate of tissue failure as estimated by the increase 
in compliance, C after four steps of disease progression.  (B) LVRS and bLVR 
reduction to 20% yielded the longest predicted survival estimated as the number 
of broken elements to reach a 60% increase in C from baseline.  (C) Even greater 
improvements were observed for the relative benefit index, which represented a 
measure of quality of life.  For all cases, mean values for LVRS and bLVR 
reduction to 20 or 40% (blue bars) were normalized by projected outcomes without 
treatment (open bars), error bars represent standard deviations. *Indicates values 
significantly larger than controls, **indicates values significantly higher than 






Figure 3-7.  Estimation of Survival and Quality of Life.  Dashed curves represent 
changes in compliance, C with and without lung volume reduction.  Predicted 
survival was estimated as the number of broken elements to reach a 60% increase 
in C from baseline (open circles).  The combined relative benefit index, which 
represented a clinical measure of quality of life, was defined as the area between 
the dashed curves and the threshold line (solid line), such that larger values 
corresponded to greater improvements following lung volume reduction.  The area 
representing simulations without lung volume reduction (open region) was 







Figure 3-8.  Long-term Progressive Changes in Network Stress. Mean values for drop in σ during 
emphysema progression before intervention (left) and then following LVRS (center) and bLVR 
(right).  Changes in σ may reflect variations in transpulmonary pressure for the system at FRC.  
Disease progression was characterized by the cumulative number of broken elements and shown 
as a percentage of the total number of elements in the network, error bars represent standard 
deviation.  Networks were divided before treatment (squares) and after LVRS (triangles) to 
illustrate differences between LVRS responders (N=8, dark blue) and marginal- responders (N=6, 
grey).  All networks (N=14) shown for bLVR reduction to 20% (green circles) and 40% (open 






Figure 3-9.  Power Law Analysis of Responses to Lung Volume Reduction.  For 
each treatment group, we calculated the histogram of forces across all networks 
using log-spaced binning, scaled the counts by the corresponding bin width, and 
then normalized the area under the curve to unity to obtain the probability density 
function.  A simple power law function, Probability ~ Forceα, was fitted to the 
linear portion of the data corresponding to the tails of the distributions plotted on 
a log-log graph.  (A) Probability density functions of force distribution directly 
before and after lung volume reduction.  (B) Values of exponent α, root mean 
squared error (RMSE), and R2 for the simple power law functions fitted to the data.  
Note that the magnitude of α decreases for treatment groups with larger immediate 
drops in C, suggesting that more heavily skewed force distributions may contribute 
to functional improvements after lung volume reduction.  For marginal-
responders, the inability to introduce high force element after LVRS may explain 
the observation of a softer overall tissue and smaller changes in C.  Interestingly, 
this would indicate a rare occurrence when heterogeneity in the lung is beneficial 





CHAPTER 4– Evaluation of Follow-up CT in Patients with COPD 
Findings from this work are currently under review for publication as an original research 
article entitled “Low-Attenuation Super Clusters Drive Emphysema Progression in 
COPD.”  Special thanks to Drs. Susumu Sato, Shigeo Muro, and Toyohiro Hirai at Kyoto 
University, Japan for their generous collaboration on this project. 
 
4.1 Introduction 
Emphysema is defined as the progressive destruction and hyperinflation of the lung 
parenchyma found in chronic obstructive pulmonary disease (COPD).  On computed 
tomography (CT), emphysematous lung areas with reduced tissue density appear as regions 
of low-attenuation [17], [115], [122]–[124].  Previous studies of disease progression, 
severity, and spatial pattern have largely focused on individual, or an average of, two-
dimensional (2D) CT slices of the lungs [40], [41], [43].  Despite advancements in our 
understanding of the underlying pathophysiologic mechanisms, questions still remain as 
this segmental approach may not represent three-dimensional (3D) processes throughout 
the whole lung. 
Percent of low-attenuation lung tissue is often used to characterize the location and 
severity of emphysematous destruction [122]–[125].  Distributions of low-attenuation 
areas, or LAAs (i.e., contiguous emphysema pixels in 2D axial CT slices) are known to 
approximately follow a straight line on a log-log graph and thus, are considered to be a 
power law [17].  The slope of this distribution tends to flatten with worsening emphysema, 




pattern and progression of disease.  Clinical studies have used this index to track annual 
changes in disease severity [40], [41] and to evaluate treatment responses[43].  More 
importantly, however, computational models based on this phenomena revealed that tissue 
rupture was a key mechanism of emphysema progression, demonstrating that mechanical 
tissue failure and coalescence of neighboring LAAs produced distributions of LAA sizes 
closely matching those observed on CT [15], [17]. 
Recent studies [16], [18], [28] suggest that tissue adjacent existing emphysematous 
regions experience abnormal biomechanical stresses during breathing, which may 
propagate disease by facilitating mechanical failure of the surrounding healthy tissue.  This 
penumbra of mechanically affected lung is associated with declining pulmonary function 
and has been termed “lung at-risk” for emphysema.  Given the complex, spatial 3D 
interdependence between healthy and affected lung tissue, analyses of 2D CT slices may 
be limited by including only in-plane mechanical interactions.  Thus, the aim of this study 
is to evaluate the sizes of low-attenuation volumes, or LAVs (i.e., contiguous emphysema 
voxels in 3D compared to 2D LAAs), as a quantitative disease assessment during annual 
follow-up in patients with COPD.  Specifically, we hypothesize that LAVs follow a power 
law distribution, similar to LAAs, which better characterizes emphysema progression by 






4.2.1 Study Population, Imaging, and Pulmonary Function 
De-identified CT scans and pulmonary function tests (PFTs) were acquired from a 
prospective observational COPD cohort database at the Kyoto University Hospital (Kyoto, 
Japan).  Scanning protocols and PFTs were performed as reported previously [41].  Briefly, 
baseline inspiratory CT scans and PFTs were obtained for COPD patients with GOLD stage 
I-III (N=12), and control patients without COPD (N=14).  For patients with COPD, two 
follow-up CT scans were performed approximately one year apart. 
4.2.2 CT Image Processing 
Lung segmentation was performed in Slicer (v4.5.0-1) using the Chest Imaging 
Platform (Applied Chest Imaging Laboratory, Brigham and Women’s Hospital) and 
Airway Segmentation (University College Cork) extension modules.  Full 3D structures of 
the lung parenchyma, excluding large airways and vessels, were then imported, 
reconstructed, and evaluated using custom scripts in MATLAB (R2016a, MathWorks, 
Natick, MA).  LAVs corresponding to regions with low tissue density were defined as 
contiguous voxels with Hounsfield unit (HU) values <–960 and 6-way connectivity (i.e., 
voxels sharing a common surface) [41], [126].  The percentages of all voxels in the lung 
field below threshold (%LAVtot) were calculated for each CT scan. 
4.2.3 Analysis of LAV Sizes 
Distributions of LAV sizes were evaluated at each time point for the left and right 




is the cumulative number of LAVs larger than or equal to size 𝑋, and 𝐾 is proportional to 
the total number of LAVs (LAN).  The exponent 𝐷 corresponds to the magnitude of the 
slope of the distribution, which was obtained from the regression between log	(𝑌)  vs 
log	(𝑋).  Outliers to the fitted power law relation were semi-automatically identified as 
LAVs with squared residuals greater than a pre-determined threshold of 0.5 and volumes 
of at least 100mL.  Although these parameters were manually selected, LAV outliers were 
confirmed by visual inspection to be reliably distinct from the remaining distribution as 
shown in Figure 4-1. 
4.2.4 Computational Modeling 
Binary masks representing the lung parenchyma were generated from each CT 
scan.  All lung voxels were initially considered to be healthy and non-emphysematous.  
Then 2-7% of all voxels were randomly changed from healthy to emphysema to seed the 
initial conditions.  To simulate disease progression, 1% of the total number of voxels were 
incrementally changed from healthy to emphysema until the simulated %LAVtot matched 
the corresponding CT scan.  For the random model, healthy voxels were selected and 
changed to emphysema with equal probability. 
In the non-random model, we introduced an estimate of local mechanical inter-
dependence between voxels by convolving a Gaussian kernel (µ=2, size=3x3x3) with a 
binary mask of existing emphysema voxels in 3D.  The smoothing kernel simulated the 
mechanical influence from neighboring voxels, such that the probability of changing a 
healthy voxel to emphysema was directly proportional to the number of emphysema voxels 




existing LAVs.  As before, 1% of the voxels were incrementally changed to emphysema 
until the simulated %LAVtot matched the corresponding CT scan.  The local probabilities 
were recalculated between each step of disease progression.  Both the random and non-
random models were simulated for each subject at all time points. 
4.2.5 Statistical Analysis 
Two-tailed t-test was used to compare baseline demographics between control and 
COPD groups, as well as estimates of 𝐷 .  The Pearson correlation coefficient was 
calculated to evaluate trends for estimates of lung function and structural parameters.  
Annual change was defined as the difference between consecutive CT scans during follow-
up, with significance determined by one sample t-test.  One-way repeated measures 
analysis of variance (ANOVA) was used to compare %LAVtot between groups.  Percent 
error between model simulations and CT was calculated as follows: 
%	𝑒𝑟𝑟𝑜𝑟 = 100 ∙
|𝜉l[mno − 𝜉pq|
𝜉pq
 Equation 4-1 
where 𝜉  is the parameter of interest.  Two-way (ANOVA), with factors selected to be 
model type and parameter, was used to detect differences in percent error between random 
and non-random model simulations.  Holm-Sidak, Dunn’s, and Tukey tests were used to 







Patient demographics for control and COPD groups at baseline are given in Table 
4-1.  Groups did not differ by body mass index (BMI).  Patients with COPD were older 
(p=0.035) and had on average 33.3±19.9% lower percent of predicted forced expiratory 
volume in one second (%FEV1) compared to controls (p<0.001).  Smoking history was 
83.8±40.8 pack-years in the COPD group.  Five patients received long-acting 
anticholinergic (e.g., tiotropium) or b-agonist (e.g., salmeterol) therapies according to 
standards of treatment.  COPD patients were evaluated annually at two additional follow-
ups. 
4.3.1 Distributions of LAV Cluster Sizes 
We observed distinct differences in distributions of LAV sizes between the control 
and COPD groups.  While distributions in the former group were well described by the 
power law in Equation 2-1, this relationship unexpectedly failed to consistently describe 
all LAVs for those in the COPD group.  This was primarily a result of a few individual 
LAV outliers that did not follow the straight line fit (Figure 4-1).  These outliers were 
termed “super clusters” due to the fact that their volumes were orders of magnitude larger 
than any remaining LAV clusters in the distribution.  In such cases, the super clusters were 
excluded and the sizes of remaining LAVs were refitted to recover a power law distribution 
with an adjusted %LAV (%LAVadj).  Comparing groups at baseline, the controls had 
statistically higher estimates of the distribution exponent 𝐷 (1.53±0.21) than the COPD 




COPD compared to controls, despite comparable values of %LAVadj (13.8±4.5% versus 
13.6±4.4%, p=0.904). 
4.3.2 Analysis of the Super Cluster 
We found that super clusters were relatively common in the COPD group, occurring 
in 9 of 12 patients, while none were observed in the control group.  Values of %LAVtot for 
patients with super clusters were significantly higher compared to COPD and control 
patients without them, p<0.001 (Figure 4-2A).  The probability of the emergence of a super 
cluster as a function of %LAVtot (Figure 4-2B) showed a sharp transition going from 0 to 
1 in a narrow range (10th and 90th percentiles of 15.6 and 25.1%, respectively) that was 
well-described by a three-parameter sigmoidal model (R2>0.999).  Lobar analysis of super 
cluster location (Table 4-2) revealed these pathologic structures were more or less divided 
between isolated clusters in single lobes and inter-lobar spanning clusters (58.2% versus 
41.8%, respectively). 
Super cluster volume (𝑉=>) was strongly correlated with %LAVtot, r=0.950 (Figure 
4-3A).  To account for inter-subject variability, 𝑉=>  estimates were normalized by low-
attenuation volume (𝑉?<@∗ ) and CT-derived total lung volume (𝑉A?@∗ ), both of which 
demonstrated similar correlations with %LAVtot, r=0.827 and r=0.943, respectively 
(Figure 4-3B).  As shown in Table 4-3, 𝑉=>  was significantly correlated with decreased 
FEV1, %FEV1, ratio between FEV1 and forced vital capacity (FEV1/FVC), diffusing 
capacity of the lung for carbon monoxide (DLCO), and DLCO divided by alveolar volume 




Alveolar-arterial (A-a) gradient.  Comparing these measurements with the normalized 
volume, 𝑉A?@∗  yielded similar correlations between parameters of lung structure and 
function, including an additional correlation with arterial partial pressure of oxygen (P8O:).  
Finally, comparing lung volumes (Table 4-4) revealed 𝑉=> was inversely correlated with 
vital capacity (VC), inspiratory capacity (IC), and ratio between IC and total lung capacity 
(TLC). 
4.3.3 Annual Changes in Lung Structure and Function during Follow-up CT 
Table 4-5 shows annual changes for parameters of lung structure and function over 
2-year follow-up.  Statistically significant increases were observed in %LAVtot, 𝑉=>, and 
𝑉A?@∗  while FEV1 and %FEV1 decreased.  Figure 4-4 depicts the evolution of super cluster 
structure during annual follow-up in a representative patient.  Note the merging of two 
neighboring super clusters during follow-up, resulting in a massive defect spanning nearly 
the entire lung.  Comparing relationships between annual changes in lung structure, we 
found that ∆𝑉A?@∗  increased linearly with ∆𝑉=> (r=0.883) while ∆𝐷 and ∆LAN were closely 
correlated with ∆LAVadj (r=-0.814 and r=0.905, respectively). 
4.3.4 Computational Modeling of Super Cluster Emergence 
We also examined the feasibility of reproducing the CT-derived distributions of 
LAV sizes using (1) a random, or (2) a non-random probabilistic model (Figure 4-5).  The 
latter was designed to represent the mechanical force-driven mechanism of tissue failure 
in emphysema [14], [17].  Computational simulations (Figure 4-6) with the non-random 




to those calculated from CT in each patient.  In contrast, the random model overestimated 
%LAVadj, 𝐷, and LAN while underestimating 𝑉=> and 𝑉A?@∗ .  For subjects with mild COPD, 
the random model actually generated no super clusters at all.  Comparing the accuracies of 
both models, the non-random model yielded significantly lower percent errors for all 
calculated parameters (p<0.001). 
 
4.4 Discussion 
In this study, we evaluated CT-derived distributions of LAV sizes as a quantitative, 
3D assessment of COPD progression.  While most LAV sizes generally followed a simple 
power law, we found that increasing disease severity was marked by the emergence of a 
few uniquely large LAV outliers, which deviated from the rest of the distribution.  
Although not observed in the control group and patients with early stages of COPD, these 
“super cluster” outliers were associated with clinical measures of lung function, including 
%FEV1 and DLCO suggesting a potential role in disease progression.  Moreover, we found 
that a probabilistic, but not random, personalized computational model simulating 
emphysematous tissue failure generated distributions of LAV sizes and super cluster 
features similar to those observed on CT. 
The observation of 3D super clusters deviated from our original hypothesis, which 
assumed all distributions of LAV sizes followed a power law.  This was unexpected as 
LAAs from 2D lung CT slices are known to follow such a relationship [17], [40], [41].  
The apparent lack of super clusters in 2D is due to structural under sampling, whereby the 




permitted by 3D reconstruction.  This could result from the irregular geometry of the 3D 
super cluster, such that re-slicing the super cluster into 2D images reveals a distribution of 
non-contiguous LAAs in each slice, despite their known connectivity in 3D.  Refitting the 
distributions of LAV sizes after excluding the super cluster demonstrated that the 
remaining LAVs did follow a single power law (Figure 4-1) with values of the exponent 𝐷 
comparable to the 2D estimates originally reported by Mishima et al. [17].  This divergence 
between the two disease regions (i.e., low-attenuation voxels within and outside the super 
cluster) may then indicate a different progression for super cluster formation and 
expansion. 
For this cohort, super clusters were first detected in patients with >15% LAVtot and 
became well-established in all patients >30% LAVtot (Figure 4-2).  Disease status below 
the lower limit likely corresponds to the early stages of emphysema and chronic lung 
inflammation [115], [117], which progresses via mechanical failure of the enzymatically-
weakened parenchyma [9], [14], [15], [17], [45].  Recently, Bhatt et al. [16] reported that 
healthy lung adjacent diseased tissue experiences altered stretch patterns during breathing, 
which could predispose these regions to increased risk for emphysema.  Based on our 
findings, we propose the following mechanism of progression: first, sustained tissue 
rupture enlarges existing LAVs until the largest collide, in part due to the finite volume of 
the lung.  This event gives rise to the sudden, phase transition-like, emergence of an 
outlying super cluster in 3D.  Once formed, its substantial size, with an increased regional 
compliance, imposes abnormal and heterogeneous biomechanical stresses on neighboring 




Positive feedback from this growth favors continued expansion of the super cluster over 
other diseased regions.  The progression outlined here is supported by the strong correlation 
between 𝑉=> and disease severity, and further, by the fact that super clusters accounted for 
a larger fraction of total lung volume with increasing %LAVtot (Figure 4-3).  Changes in 
%LAVadj, 𝐷 and LAN (Figure 4-4) additionally suggest that super cluster expansion was 
associated with assimilation of smaller, remaining LAVs.  Moreover, the sharp transition 
in Figure 4-2B would imply that super cluster emergence is a fundamental feature of 
emphysema progression, which embodies a general mechanism of force-induced, tissue 
destruction in 3D.  This central pathway of parenchymal deterioration is independent of 
the various environmental or biochemical factors inciting disease development and 
suggests that early intervention to disrupt this process may substantially delay or even 
prevent the onset of more severe lung decline, providing a more efficacious alternative to 
symptom management. 
To help interpret our observations, we compared two personalized computational 
models of emphysema.  The non-random model (which favored disease progression in 
healthy tissue near emphysematous regions) closely approximated the disease patterns 
observed on CT (Figure 4-6).  In contrast, the random model (which assigned all voxels 
the same probability of becoming emphysema) failed to generate comparable distributions 
of LAV sizes, including underestimation of 𝑉=> in nearly every patient.  These findings 
establish that super cluster formation was not solely due to spatial restrictions of the finite 
lung, but rather emerged via outward growth and directed coalescence with nearby LAVs.  




diseased tissue, which appear to be essential for the structural changes observed with 
worsening emphysema.  This is consistent with the aforementioned “lung at-risk” view 
[16] that suggests emphysema progression occurs within a penumbra of healthy lung 
surrounding existing diseased regions. 
Super cluster structure was also strongly correlated with clinical measures of lung 
function.  Estimates of FEV1 indices (Table 4-3) were inversely related to 𝑉=> indicating 
that super cluster size contributed to severity of flow limitation.  This may reflect small 
airway disease within areas of the super cluster [115]; however, reduced traction and 
airway-parenchymal tethering associated with super cluster enlargement might play a role 
by promoting airway collapse (and thereby reducing FEV1) in neighboring lung regions 
[81], [82].  Interestingly, there was no correlation between 𝑉=> and RV, which may suggest 
regions of the super cluster remained reasonably ventilated.  Nevertheless, the inverse 
relationship between DLCO and 𝑉=> , which was not detected by 2D analysis [17], likely 
reflects a loss of alveolar surface area available for gas exchange [127] due to the structural 
defect created by expansion of the super cluster.  One explanation for such strong 
correlations is the extreme size of the super cluster, which can span the boundaries of the 
lung as in percolation theory [128].  A defect of this size must certainly compromise lung 
function and affect parenchymal stretch during tidal breathing due to the dramatically 
reduced tissue density and elevated compliance. 
3D CT reconstruction of the lungs are used now more than ever to assess structural 
and functional changes in pulmonary diseases [129]–[131].  Although others [132]–[134] 




on a volumetric classification, this is the first study to explore these prominent clusters as 
independent features of disease severity and progression.  As an additional characterization 
of LAV morphology, we estimated the fractal dimension (𝐷3), which is a measure of space-
filling capacity or complexity, for each super cluster (Figure 4-7).  The total fractal 
dimension for all remaining clusters (𝐷3∗) excluding the super cluster was also estimated.  
We found that 𝐷3 was correlated with 𝑉?<@∗ , suggesting the super clusters more efficiently 
filled the lung parenchyma as their size increased, while 𝐷3∗ primarily depended on LAN.  
Annual changes in 𝐷3 were statistically significant (p=0.043).  Interestingly, super clusters 
spanning adjacent lobes were found in several cases.  Although inspection of fissure 
integrity was beyond the scope of this study, this could indicate that intact fissures provide 
a mechanical barrier to emphysema, which are circumvented via interlobar collateral 
ventilation pathways in those super clusters spanning adjacent lobes. 
There are some limitations with this study, primarily the small cohort size.  
However, all patient data was acquired using the same CT scanner to minimize variability 
between scans, and super clusters were consistently observed at higher %LAVtot.  Annual 
changes in PFT measurements were not statistically significant for some indices, despite 
median values similar to other CT studies [40], [41], [126], which could be due to the 
sample size.  Our findings cannot be generalized to GOLD stage IV as no subjects were 
included in this study.  Nevertheless, the COPD group included 𝑉?<@∗  >0.8 suggesting more 
severe stages of disease would likely exhibit similar features of super cluster progression.  
For this study, we used a threshold of -960 HU; however, the linear correlation between 




HU (Figure 4-8).  Finally, our computational model of emphysema assumed a fixed lung 
volume without elastic effects.  Although we did not directly simulate tissue mechanics, 
the stochastic design approximated the overall lung at-risk for disease progression, which 
we validated in a 2D elastic spring network model (not shown).  Moreover, a previous 2D 
model reproduced annual changes in emphysema structure using a similar approach [41]. 
In summary, we report the emergence of 3D super clusters in patients with COPD 
and describe their morphological progression during follow-up CT.  These large structural 
defects are associated with decreased lung function and could play a central role in 
emphysema progression by altering the biomechanical environment of adjacent healthy 
tissue.  This insight may allow for the design of more rational, patient-specific therapies 
and treatment strategies.  More studies are needed to determine whether these super clusters 









Table 4-1.  Baseline demographics of control and COPD patients 
 Control (N=14) COPD (N=12) p-value 
Age (years) 51.0 (41.0, 72.0) 68.6 (64.8, 73.0) 0.035* 
Sex 
(male:female) 5:9  12:0  -- 
Body mass index, 
BMI 22.4 (20.6, 24.1) 22.6 (20.0, 24.5) 0.881 
Smoking history 
(pack-years) --  75.5 (47.6, 111.8) -- 
FEV1 (L) 2.87 (1.82, 3.20) 2.10 (1.80, 2.60) 0.127 
%FEV1 (%) 102.0 (95.2, 112.1) 74.4 (60.9, 84.4) <0.001* 
GOLD stage 
(I/II/III/IV) --  5/5/2/0  -- 
Tiotropium (%) --  16.7  -- 
Salmeterol (%) --  25.0  -- 
Data expressed as medians (25th and 75th percentiles).  *Statistically significant, p<0.05.  Forced 







Table 4-2.  Relative lobar frequency of super clusters in patients with COPD (N=9) 





RU 14.5 -- 
54.5 
RM 0.0 -- 
RL 12.7 -- 
RU-RM -- 14.5 
RL-RM -- 1.8 
RU-RM-RL -- 10.9 
LU 21.8 -- 
54.5 LL 9.1 -- 
LU-LL -- 14.5 
Total 58.2 41.8  






Table 4-3.  Correlation between lung function and super cluster size in patients with COPD 
(N=9) 
 Volume, 𝑽𝒔𝒄 Normalized Volume, 𝑽𝑻𝑳𝑽∗  
 𝝆 p-value 𝝆 p-value 
FEV1 -0.701 <0.001* -0.635 <0.001* 
%FEV1 -0.748 <0.001* -0.641 <0.001* 
FVC -0.376 0.053 -0.315 0.110 
%FVC -0.181 0.365 -0.061 0.762 
FEV1/FVC -0.813 <0.001* -0.734 <0.001* 
DLCO -0.696 <0.001* -0.730 <0.001* 
DLCO/VA -0.810 <0.001* -0.786 <0.001* 
pH 0.089 0.667 -0.050 0.809 
PaO2 -0.388 0.050 -0.418 0.033* 
PaCO2 0.042 0.839 -0.030 0.886 
A-a gradient 0.294 0.145 0.345 0.085 
Data expressed as medians (25th and 75th percentiles).  *Statistically significant, p<0.05. Blood 
gasses were not collected for one subject and thus, excluded from the analysis.  Forced expired 
volume in one second after a maximal inhalation (FEV1), percent of predicted FEV1 (%FEV1), 
forced vital capacity (FVC), percent of predicted FVC (%FVC), diffusing capacity of the lung for 
carbon monoxide (DLCO), alveolar volume (VA), arterial partial pressure of oxygen (PaO2), arterial 






Table 4-4.  Correlation between lung volumes and super cluster size in patients with COPD 
(N=9) 
 Volume, 𝑽𝒔𝒄 Normalized Volume, 𝑽𝑻𝑳𝑽∗  
 𝝆 p-value 𝝆 p-value 
VC (L)  -0.428 0.026*  -0.416 0.031* 
%VC (%)  -0.292 0.139  -0.252 0.204 
TV (L)  -0.070 0.729  -0.064 0.751 
ERV (L)  -0.150 0.456  -0.134 0.507 
IRV (L)  -0.205 0.305  -0.236 0.236 
IC (L)  -0.466 0.014*  -0.461 0.016* 
FRC (L) 0.080 0.693  -0.094 0.639 
RV (L) 0.239 0.230 0.051 0.801 
TLC (L)  -0.197 0.325  -0.332 0.091 
RV/TLC 0.296 0.135 0.166 0.409 
IC/TLC  -0.468 0.014*  -0.368 0.059 
Data expressed as medians (25th and 75th percentiles).  *Statistically significant, p<0.05.  Vital 
capacity (VC), tidal volume (TV), expiratory reserve volume (ERV), inspiratory reserve volume 
(IRV), inspiratory capacity (IC), functional residual capacity (FRC), residual volume (RV), total 







Table 4-5.  Average annual change in lung function and structure during follow-up in patients 
with COPD 
 D/year p-value 
LUNG FUNCTION (N=12)   
FEV1 (L)  -0.070  (-0.160, -0.020) 0.014* 
%FEV1 (%) -1.862  (-5.367, -0.223) 0.040* 
FVC (L)  -0.160  (-0.295, 0.005) 0.095 
%FVC (%) -3.382  (-8.397, 0.646) 0.187 
FEV1/FVC (%)  -0.204  (-1.974, 1.833) 0.408 
DLCO (mL min-1 mmHg-1) -0.910  (-1.965, 0.390) 0.149 
DLCO/VA (mL min-1 mmHg-1 L-1) -0.110  (-0.370, 0.200) 0.290 
LUNG STRUCTURE (N=9)   
%LAVtot (%) 0.387  (-0.479, 2.995) 0.015* 
𝑉yz  (L) 0.026  (-0.011, 0.096) 0.014* 
𝑉{r|∗  0.013  (-0.009, 0.050) 0.212 
𝑉q{|∗  0.009  (-0.002, 0.025) 0.035* 
%LAVadj (%) -0.467  (-1.249, -0.138) 0.993 
𝐷 0.000  (-0.035, 0.045) 0.636 
LAN -17382  (-30015, 8351) 0.784 
Data expressed as medians (25th and 75th percentiles).  *Statistically significant, p<0.05.  Forced 
expired volume in one second after a maximal inhalation (FEV1), percent of predicted FEV1 
(%FEV1), forced vital capacity (FVC), percent of predicted FVC (%FVC), diffusing capacity of 
the lung for carbon monoxide (DLCO), alveolar volume (𝑉r), total percent low attenuation volume 
(%LAVtot), super cluster volume (𝑉yz), volume normalized by total low attenuation volume (𝑉{r|∗ ) 
or total lung capacity (𝑉q{|∗ ), adjusted percent low attenuation volume excluding super cluster 






Figure 4-1.  Representative LAV cluster size distributions for control and COPD 
patients fitted to a power law (solid lines).  The super cluster (arrow) corresponds 
to the LAV outlier roughly three orders of magnitude larger than the remaining 
distribution.  Inset: values of D were significantly lower in patients with COPD 






Figure 4-2.  The super cluster is a characteristic feature of advanced parenchymal 
destruction in emphysema.  (A) COPD patients with super clusters had 
significantly larger %LAVtot compared to COPD and control patients without 
them.  (B) The probability of finding a super cluster increased with 
%LAVtot.  Dashed lines represent 10th and 90th percentiles, the solid red line shows 






Figure 4-3.  (A) Super cluster volume (𝑉=>) was linearly related to disease severity 
as characterized by %LAVtot.  (B) Normalizing by low attenuation volume (𝑉?<@∗ , 
open circles) and total lung volume (𝑉A?@∗ , filled circles) yielded similar trends.  






Figure 4-4.  (A) Super cluster progression in the same patient at baseline and annual follow-up; 
boundaries are shown by shaded regions.  (B) Annual changes in normalized volume (∆𝑉A?@∗ ) 
increased linearly with super cluster volume (∆𝑉=>), indicating super cluster growth was not due to 
hyperinflation of the entire lung.  (C-D) Annual changes in distribution exponents (∆𝐷) and number 
of LAVs (∆LAN) were associated with changes in adjusted percent low attenuation volume 






Figure 4-5.  Schematic describing the probabilistic computational models of 
emphysema.  The non-random model (red) favored disease progression in regions 
near existing emphysema, while the random model (blue) had no spatial 
bias.  Disease progression was simulated for each patient using the binary lung 






Figure 4-6.  Computational simulations using the non-random model yielded LAV distributions 
and super cluster structures similar to those observed on CT, with significantly smaller percent 
error compared to the random model, p<0.001.  Percent low attenuation calculated after excluding 
super clusters (%LAVadj); distribution exponent (𝐷); total number of LAVs (LAN); super cluster 






Figure 4-7.  The fractal dimension of the super cluster, 𝐷3  was calculated as the Minkowski-
Bouligand dimension using the box counting method: 𝑀 ∝ 𝐿HI} where 𝑀 is the number of cubes 
with length 𝐿 required to cover the super cluster.  (A) 𝐷3 was linearly related to normalized super 
cluster volume (𝑉?<@∗ ), while (B) the fractal dimension calculated for the remaining clusters, 𝐷3∗ 
was correlated with the total number of clusters, LAN as would be expected.  (C) Annual changes 



































































































Figure 4-8.  Relationship between super cluster volume, 𝑉=>  and %LAVtot was 
preserved across a range of LAV thresholds. 
 
LAVtot (%)
























CHAPTER 5– Cyclic Stretching of CSE-Exposed Precision-Cut Lung Slices 
Findings from this project are currently in preparation for publication as an original 
research article titled “Cyclic Stretch During Exposure to Cigarette Smoke Extract Induces 
IL-1b in Precision-Cut Lung Slices.” 
 
5.1 Introduction 
Precision-cut lung slices (PCLSs) have emerged as a valuable experimental 
preparation for probing structure-function relations in the healthy and diseased lung.  The 
PCLS has two primary advantages: (1) the native extracellular environment is maintained 
so that functional relationships among the airways, parenchyma, and resident cells therein 
are preserved [71]; and (2) it can be used to recapitulate in vivo exposure to toxic substances 
[73], [75], [76], [135]–[137] and pharmacologic therapy [77]–[80].  Accordingly, this 
approach is particularly well-suited to explore potential factors underlying diseases such 
as COPD, with pathologic remodeling of the airways and emphysematous parenchymal 
destruction secondary to repeated noxious chemical exposure [1].  However, the lung is 
continuously and rhythmically stretched during tidal breathing in vivo and thus, demands 
similar dynamic conditions for comparisons ex vivo [9].  While previous work has 
demonstrated the feasibility of stretching lung slices [86], [88], [89], these methods, to 
date, are relatively low-throughput and have yet to be applied in the context of COPD.  
PCLSs are routinely used to evaluate mechanical interactions between the airways 
and parenchyma [74], [81]–[84], [87], [138], [139], demonstrating their applicability in 




examined similar changes in enzymatically-digested lung slices mimicking emphysema 
[84]; however, these data are limited by the absence of superimposed stretch, which has 
been shown to influence cellular and enzymatic maintenance of tissue properties [94], 
[140].  In contrast, Margulies et al. have investigated changes in cell behavior following 
cyclic stretching of lung slices [88], [95], a phenomenon known as mechanotransduction 
[46].  They present this work in the clinical setting of ventilator-induced lung injury (VILI), 
highlighting nuclear translocation of NF-kB and oxidative stress responses throughout the 
whole-tissue.  It has been suggested that analogous mechanisms could facilitate 
emphysema progression in the lung via increased secretion of pro-inflammatory cytokines, 
or elevated enzyme release and matrix turnover [9].  However, comparable and potentially 
transformative studies aimed at elucidating the possible role of mechanotransduction in 
COPD pathogenesis and progression are lacking. 
Here, we report the design and implementation of a multi-well equibiaxial device 
to cyclically stretch PCLSs obtained from excised rat lungs.  Its key advantages include 
high-throughput, low variance, and the ability to deliver complex, user-defined stretch 
patterns to the entire slice.  We hypothesize that the inflammatory response following acute 
exposure to cigarette smoke extract (CSE) is stretch-dependent.  To test this, we will 
compare the pro-inflammatory cytokine interleukin 1-b for different stretch patterns in lung 







5.2.1 Animal Protocol 
Protocol #16-025 was reviewed and approved by the Boston University 
Institutional Animal Care and Use Committee (IACUC).  Male Sprague-Dawley rats 
(N=10) with body weight 343.8±60.2 g were sedated via i.p. injection of xylazine (10 
mg/kg) and ketamine (90 mg/kg).  After ensuring appropriate depth of anesthesia and 
analgesia, animals were euthanized via abdominal aortic exsanguination.  The lungs were 
excised and insufflated via tracheostomy with 10-12 mL of 1.5% low-melt agarose 
(HyAgarose, ACTGene Inc., Piscataway, NJ) in Hanks’ buffered salt solution (HBSS, 
Sigma) at 37° C, according to previous techniques [75].  Lung slices were then placed on 
ice for 15 minutes to allow solidification of the agarose. 
5.2.2 Precision-Cut Lung Slices (PCLSs) 
Lung lobes were separated, trimmed to fit the tissue stage, and then sliced in cooled 
HBSS with thickness ~500 µm using a vibratome (752M Vibroslice, Campden Instruments 
Ltd., England).  The vibratome tissue stage was modified to include an adjustable, 
cylindrical sleeve that was filled with 1.5% low-melt agarose to help stabilize the lung lobe 
during slicing.  PCLSs were then “punched” using either a 6 or 10 mm coring tool 
(Acuderm Inc., Fort Lauderdale, FL) to generate round, symmetric slices.  Punching the 
tissues after slicing the entire lobe was found to yield a greater amount of material 
compared to coring the lung lobes prior to slicing.  PCLS were then moved to Dulbecco’s 




and amphotericin B (Antimycotic-Antibiotic, Gibco).  To facilitate removal of residual 
agarose and other cellular debris, media was changed every 30 min for 0-2 h after slicing, 
every 1 h for 2-4 h,  every 2 h for 4-8 h, and every 24 h thereafter, similar to previous 
methods [88], [89], [95].  Lung slices were incubated under standard conditions of 5% CO2 
at 37° C and allowed to recover overnight. 
5.2.3 MTS Assay 
PCLS viability was assessed via MTS assay, which is a colorimetric measure of 
cell metabolic activity [141].  MTS is comprised of a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxyme- thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] 
and the electron coupling reagent, phenazine ethosulfate, which is thought to be reduced 
by NAD(P)H-dependent dehydrogenase enzymes.  The total formazan product yielded by 
this reduction, in proportion to the number of metabolically healthy or active cells, can be 
quantified by measuring the absorbance at 490 nm.  In this study, the colorimetric MTS 
assay was used according to manufacturer’s specifications.  Individual lung slices (6mm) 
were placed in HBSS with 20 µL of MTS reagent added.  Following incubation for 1.5 h 
at 37° C, the supernatant was removed to a 96 well plate for measurement of optical density. 
5.2.4 Preparation and Potency of Cigarette Smoke Extract (CSE) 
CSE solutions were prepared fresh by bubbling two cigarettes (Marlboro Red), with 
the filters removed, through 20 mL of DMEM at a rate of 1.0 L/min to yield a stock solution 
of 0.1 cig/mL.  Next, the solutions were sterile filtered using a 0.22 µm pore size membrane 




other bacterial particles.  To determine the CSE dose response curve, the stock solution 
was diluted and (N=93) 6 mm lung slices were incubated in 6 well plates for 12 h with CSE 
concentrations ranging from 0.001 to 0.050 cig/mL (~3 slices per 3 mL of solution in each 
well).  Following incubation, individual slices were rinsed with warmed HBSS to remove 
any residual solution containing the CSE-media mix.  PCLS were then transferred to a 96 
well plate for assessment of viability via MTS assay as described above. 
5.2.5 Multi-Well Stretcher Calibration 
The multi-well stretching system pictured in Figure 5-1 was built and calibrated 
based on previous designs [92], [142].  We also designed a 6-well, re-usable “flex-frame” 
with an elastic, silicone membrane (Specialty Manufacturing, Inc.) for cyclic stretching of 
attached lung slices, which we validated by comparison with a commercially available 
alternative (Flexcell International Corp., Burlington, NC).  The top and bottom components 
of the flex-frame are separable, allowing for replacement of the elastic membrane between 
experiments.  Up to two flex-frames can be secured in the upper actuating stage of the 
equibiaxial stretcher, which is shifted vertically using a linear actuating motor.  As the 
stage is moved down, the basement membrane in each well is deformed around a fixed, 
cylindrical post where the surface area is related to the vertical displacement.  Conversely, 
the membrane and attached PCLS relax as the stage moves back up.  Ball bearings affixed 
to the top of the indenter posts reduce friction as the elastic membrane is stretched, 
minimizing hysteresis between loading and unloading.  A custom software interface allows 
the user to prescribe any complex stretch pattern including waveform, frequency, 




culture (5% CO2 at 37° C) incubator to perform stretching experiments under controlled, 
sterile conditions. 
To calibrate the relationship between stage displacement and membrane surface 
area, colored acrylic beads (Pēbēo, Cedex, France) were adhered to the membrane in a 
circular configuration and then tracked during quasi-static stretch to compute local area 
change.  The corresponding area strain-displacement curve was used to calibrate the 
stretcher and prescribe area strains for cyclic stretching.  Delaunay triangulation and radial 
displacement of individual beads were used to calculate the Lagrangian strain 𝐸56  of the 
elastic membrane during stretch according to the following relation [143]:  
ds: − dsW
: = 2Edada Equation 5-1 
where ds and dsW are the changes in segment lengths of each triangle, while da and da 
are the changes in position of the bead vertices.  To assess whether repeated stretch induced 
plastic deformation of the elastic membrane, this calibration procedure was repeated 
following 12 h of stretch. 
5.2.6 Experiment Protocol 
Individual unstretched lung slices were attached to the center of the elastic 
membranes in each well using 4 evenly spaced beads of cyanoacrylate glue along the tissue 
perimeter.  A single-well stretcher device designed for live-imaging [142] was used to 
assess the integrity of PCLS attachment and to validate that changes in tissue strains 
matched those calibrated in the elastic membrane during prescribed stretch (see 
APPENDIX A).  Once attached, PCLS were covered with 3 mL of media with or without 




stretched for 12 h at 1 Hz under standard incubation conditions.  To assess the effect of 
different stretch patterns, PCLS were randomly assigned to one of the following three 
stretch amplitude groups: 0% (unstretched), 5% peak-to-peak amplitude with no static 
stretch (dynamic-only), and 5% peak-to-peak amplitude superimposed on 10% static 
stretch (static+dynamic).  These waveforms were selected arbitrarily to simulate regions of 
the lungs experiencing different stretch during tidal breathing, a schematic is shown in 
Figure 5-2.  Following cyclic stretch, the PCLSs and supernatant were collected from each 
well for biochemical and mechanical analyses (N=48).  Solo.  Protease inhibitors EDTA 
(ethylenediaminetetraacetic acid) and Halt Protease Inhibitor cocktail (Thermo Scientific) 
were added to the homogenized tissue samples and supernatant, then stored at -20° C until 
further use.  PCLSs were also collected to assess tissue viability after stretching (N=49).  
Lung slices were trimmed using the 6 mm coring tool to reduce edge effects from slicing 
or the cyanoacrylate glue attachment procedure, and then evaluated via MTS as before. 
5.2.7 Western Blot 
Protein concentrations for the homogenized tissues and supernatant were 
determined using the BCA (bicinchoninic acid) colorimetric protein assay (Pierce, Thermo 
Scientific).  Proteins in an alkaline medium reduce Cu2+ to Cu1+, which can react with BCA 
to form a concentration-dependent, water-soluble complex exhibiting a strong linear 
absorbance at 562 nm.  The assay was used according to manufacturer’s specifications.  
Briefly, 5-10 µL of each sample were loaded into a 96 well plate and combined with assay 





Equal amounts of protein from each sample were separated via sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a polyvinylidene 
difluoride (PVDF) membrane, and blocked using 5% bovine serum albumin in phosphate 
buffered saline containing 0.05% Tween 20 (PBS-T).  After blocking for 2 h, the membrane 
was incubated at for 1 h room temperature with primary antibodies anti-IL-1 beta (1:250, 
Abcam) and anti-b actin (loading control, 1:5000, Abcam), washed in PBS-T 4x15 min, 
incubated with secondary antibody (anti-mouse, 1: 5000, Vector Laboratories) for 1 h, and 
then washed 4x15 min in PBS-T.  Quantitative densitometry was performed after 
chemiluminescence detection (SuperSignal West Pico Chemiluminescent Substrate, 
Pierce) and corrections were made for background and loading control. 
5.2.8 Statistical Analysis 
Data analysis and fitting were performed using MATLAB (R2016a, MathWorks, 
Natick, MA) and SigmaPlot (SigmaPlot v12.3, Systat Software, Inc., San Jose, CA).  Two-
way analysis of variance (ANOVA) was used to evaluate the influence of stretch and CSE 
on PCLS viability and IL-1b.  For all comparisons, p<0.05 was considered significant.  
CSE dose response data was fitted using a four-parameter logistic regression as follows: 
𝑦 = 𝑎 −
𝑏 − 𝑎
1 + 𝑥𝑐
m Equation 5-2 
where 𝑦 is normalized absorbance; 𝑥 is CSE concentration 𝑎 and 𝑏 are the maximum and 
minimum values possible, respectively; 𝑐 is the point of inflection; and 𝑑 is a coefficient 






Figure 5-3 shows the calibration and validation of the multi-well stretcher and flex-
frame devices.  Vertical displacement of the actuating stage yielded a nonlinear relation 
between area strain and motor position (Figure 5-3A), which was used to prescribe 
waveforms for cyclic stretching.  Note the minimal hysteresis between loading and 
unloading of the flex-frame elastic membrane.  Normal Lagrangian strains, 𝐸 and 𝐸 , 
were nearly identical, 𝜌>0.999, with negligible shear strain, 𝐸<0.0005, demonstrating 
equibiaxial strain of the elastic membrane (Figure 5-3B).  Compared to the commercially 
available Flexcell, our custom fabricated flex-frame demonstrated lower intra-well 
variance (N=6) in area strain, 0.473±0.717% versus 0.127±0.073% (Variance Mean±SD), 
particularly at larger prescribed strains (Figure 5-3C).  Finally, plastic deformation of the 
membrane was not observed following 12 h of cyclic stretching, with comparable changes 
in area strain before and after stretch, 𝜌=0.998 (Figure 5-3D). 
Figure 5-4 shows the effects of CSE and cyclic stretch on tissue viability.  PCLS 
viability decreased with CSE concentration as expected (Figure 5-4A).  The corresponding 
dose response curve was well characterized by a four-parameter logistic model (R2=0.893), 
yielding an EC50 value of 0.018 cig/mL, which corresponds to the CSE concentration at 
half-maximal viability.  Following 12 h of cyclic stretching (Figure 5-4B), two-way 
ANOVA detected no statistical difference in PCLS viability among different stretch 
patterns (p=0.070), CSE exposure (p=0.594), or their interaction (p=0.277), demonstrating 
that equibiaxial, cyclic stretch with CSE did not compromise tissue viability in this system. 




between CSE and cyclic stretch on IL-1b tissue content (p=0.017).  IL-1b content increased 
with stretch and was statistically higher in the CSE group at each stretch amplitude, with 
the greatest percent increase between groups observed for the 0% and 10-15% stretch 
conditions (p=0.005 and p=0.024, respectively). 
 
5.4 Discussion 
In this study, we present the design and implementation of a multi-well stretcher to 
investigate the mechanical-inflammatory response of lung tissue following acute exposure 
to CSE and cyclic stretch.  We characterize the CSE dose response curve for PCLSs and 
show that our device delivers repeatable, equibiaxial stretch without compromising tissue 
viability.  To demonstrate the utility of this system as an ex vivo model of COPD, we 
measured changes in the cytokine IL-1b, a key mediator in the inflammatory response.  
Both stretch and CSE exposure had a significant effect on the tissue content of IL-1b, with 
the greatest increase observed for the CSE static+dynamic group.  Inter-group comparisons 
revealed that the dynamic-only stretch condition yielded the smallest difference between 
control and CSE groups.  These findings (1) demonstrate the feasibility of using this system 
to recapitulate tidal breathing conditions in PCLS, and (2) identify a stretch dependent 
interaction for acute CSE exposure, suggesting that pro-inflammatory effects of cigarette 
smoke in vivo are modulated by the local mechanical environment in the lungs. 
Biomechanical forces are known to facilitate emphysema progression via 
mechanical failure of parenchymal tissue [14], [17], [94].  Although such stresses are 




produced enzymes such as elastases, collagenases, and MMPs can weaken and predispose 
tissue to failure [15].  We observed the largest IL-1b increase for the CSE static+dynamic 
group (Figure 5-5A), indicating areas of elevated tissue stresses may also experience the 
strongest inflammatory response to acute smoke exposure in vivo.  This suggests such 
regions are more susceptible to inflammation-mediated enzymatic weakening, placing 
them at even greater risk of failure by the already increased mechanical forces.  Moreover, 
we found that the unstretched and static+dynamic groups exhibited greater sensitivity to 
CSE compared to the dynamic-only group (Figure 5-5B), indicating the pro-inflammatory 
effects of acute smoke exposure in vivo may be enhanced in lung regions that are routinely 
under- or over-stretched.  These findings could explain why normal tissue adjacent existing 
emphysematous tissue, which have been shown to experience abnormal biomechanical 
stretch [16], [18], [28], seem to carry the highest risk for disease progression [15], [17], 
[96]. 
There is a paucity of data describing the mechanical-inflammatory interaction in 
the lungs.  Previous studies in tendon and uterine smooth muscle cells have demonstrated 
stretch-dependent effects for IL-1b, with downstream targets including MMPs and other 
pro-inflammatory mediators [144]–[146], while IL-1b has been shown to independently 
increase IL-6, cyclooxygenase-2 (COX-2), and MMP-1,-3, and -13, in the absence of 
stretch [147]–[149].  Moreover, cigarette smoke exposure in transgenic mice 
overexpressing IL-1b or knockout mice lacking the IL-1 receptor is known to cause 
pulmonary inflammation, leading to emphysema and small airway remodeling [150], 




and MMP-9 and -12, highlighting a key role for IL-1b in disease development.  Although 
other studies implicate IL-1a as an ‘alarmin’ signal of epithelial cell injury [152] 
responsible for increasing numbers of neutrophils and macrophages [153], [154], IL-1b 
levels in humans are chronically elevated in COPD and correlate with disease severity.  
Therefore, our findings are consistent with the pro-inflammatory role of IL-1b in COPD 
progression and suggest its stretch-dependent response to acute CSE exposure may 
exacerbate disease heterogeneity in the lungs. 
Although other studies have investigated cyclic stretch of PCLSs [86], [88], [89], 
this is the first time it has been utilized it in the context of COPD.  This is particularly 
relevant given the central role of mechanotransduction in disease progression, as discussed 
above and reviewed previously [9].  Margulies et al. have adopted a novel stitching 
technique to suture lung slices onto a silicone membrane demonstrating repeatable uniform 
stretch [88], [89], while a similar approach directly clamped the PCLS to an elastic 
membrane deformed non-uniformly by a static distending pressure [86].  Alternatively, 
Lavoie et al. developed a device to apply tidal-like breathing strains to individual airways 
by compressing the lung slice between a layer of polyacrylamide gel and a hollow indenter 
[87].  Nevertheless, these techniques can be time consuming, limited to a single PCLS, or 
constrained to a small area-of-stretch.  In contrast, the multi-well device described here 
provides simultaneous, whole-slice stretching of up to 12 samples with minimal 
preparation time.  The addition of ball bearings on the indenter posts helps to minimize 
intra-cycle hysteresis, generate equibiaxial stretch, and improve inter-cycle repeatability 




cell damage (Figure 5-3) [92].  Moreover, our custom flex-frame design is economic and 
significantly lowers inter-well variance compared to commercially available alternatives.  
Therefore, while stretcher selection is largely based on application and group preference, 
the equibiaxial stretcher presented here is ideal for high-throughput testing of acute 
exposures, either pathologic or therapeutic, under tightly-regulated, physiologic stretch 
conditions. 
Finally, CSE has been used for in vitro models of cigarette smoke exposure [62], 
[63], [155]–[158], and for small animal models [51], [52], [66], [68], [159], [160] given its 
similarity to in vivo human pathophysiology over exogenous elastase administration and 
shorter incubation time compared to direct smoke exposure.  However, it is reported less 
frequently with PCLS, making it necessary to characterize the CSE dose response curve 
and establish a sub-toxic concentration mimicking acute cigarette smoke exposure in vivo 
(Figure 5-4).  It was observed that a concentration of 0.01 cig/mL, which was similar to in 
vitro values reported in the studies above, yielded significant increases in IL-1b for each 
stretch condition with tissue viability comparable to control slices. 
There are some limitations of this study.  (1) The low-melt agarose is likely 
incompletely removed despite frequent media changes after slicing [71], [83], [88], which 
could affect the apparent stiffness and residual area of the lung slice.  Thus, care was taken 
to prepare the excised lungs in the same manner each time to minimize potential disparities 
between animals.  (2) Although IL-1b is a key mediator of inflammation, it does not 
directly reflect enzymatic activity that may weaken the lung parenchyma.  Nevertheless, 




respiratory toxicity in PCLSs [77], [135], [137].  (3) Although the MTS analysis does not 
specify local tissue viability, this can be extended with immunohistochemistry to verify 
cell origin, such as an epithelial-focused loss of viability, or live/dead imaging of stretched 
slices.  (4) The lack of circulation in the PCLS limits the study of chemotactic factors, 
including neutrophil recruitment, which participate in the inflammatory response to 
cigarette smoking [161].  (5) Unlike some single-well devices for cell stretching [162]–
[164], this platform does not facilitate live-imaging during stretch; however, flex frames 
can be removed to visual lung slices immediately after stretch.  Importantly, this multi-well 
stretcher is also suitable for parallel stretching of cells under different exposure/treatment 
conditions. 
In summary, we show that the pro-inflammatory effects of acute exposure to 
cigarette smoke extract are stretch-dependent, suggesting that mechano-inflammatory 
interactions facilitate disease progression in lung regions with abnormal biomechanical 
stresses.  These findings highlight the role of mechanotransduction as a key mediator in 
COPD, which is only appreciated through disease models that recapitulate the dynamic 
conditions of tidal breathing in vivo.  Additional studies will determine whether protective 
ventilation strategies or targeted therapeutics can potentially protect lung at-risk and 









Figure 5-1.  (A) Multi-well stretcher device for cyclic, equibiaxial stretching of 
PCLSs.  A linear motor is used to drive the vertical motion of the actuating stage.  
As the attached flexframe (C) is pulled down, the elastic membranes in each of the 
wells are deformed around stationary indenter posts with affixed ball bearings (B).  
Similarly, as the actuating stage moves back up, the membrane relaxes.  A custom 







Figure 5-2.  Lung slices were cyclically stretched for 12 h using the specified 







Figure 5-3.  (A) Calibration curve used to prescribe membrane area strain as a function of motor 
position.  Symbols represent means of N=6 wells with standard deviations smaller than symbol 
sizes.  (B) Nearly identical normal strains, Exx and Eyy, and negligible shear strain, Exy, as estimated 
by Delaunay triangulation, confirmed equibiaxial strain of the elastic membrane.  (C) For this 
system, our custom flexframe exhibited a consistently lower variance of area strain among the N=6 
wells in comparison to the commercially available flexcell (make/model).  (D) Changes in area 
strain before and after 12 h of cyclic stretching indicate unchanged mechanical properties of the 





Figure 5-4.  (A) The decrease in PCLS viability (N=93) with CSE concentration was well 
characterized (R2=0.893) by a four-compartment logistic curve (solid line) as shown with 95% 
confidence intervals (dashed lines).  Data are binned for multiple CSE concentrations, vertical and 
horizontal error bars represent SE and SD, respectively.  (B) Two-way ANOVA detected no effects 








Figure 5-5.  (A) Two-way ANOVA revealed a significant effect between CSE and stretch on 
normalized IL-1b in homogenized tissue (p=0.017).  Data (N=8) are shown as mean and SD, 
*p<0.05 and **p<0.001. Representative bands for IL-1b tissue content and b-actin loading control 
are also shown.  (B) Percent differences between CSE and control were larger for unstretched and 






CHAPTER 6– Conclusions 
 
6.1 Summary and Scientific Contributions 
The overarching goal of this dissertation was to study the effects of biomechanical 
stresses at the cell and tissue level, and on overall structural-functional changes in the lung, 
with application for clinical intervention.  We argued that tissue failure and acute 
inflammatory responses in COPD are linked to the local biomechanical stresses that cells 
experience within the parenchyma, and over time emerge as systematic patterns of lung 
decline.  In CHAPTER 4 we used follow-up CT to characterize emphysema progression in 
patients with COPD.  We demonstrated through 3D reconstruction of the lungs that super 
clusters, which are massive contiguous regions of low-attenuation tissue, represent a 
previously unrecognized, defining structural feature of emphysema that is strongly 
correlated with clinical measures of lung function.  Combined with personalized 
computational simulations of super cluster emergence, these findings suggest a new disease 
process whereby advanced emphysema progression is driven primarily by expansion of 
these dominant structural defects, rather than the coalescence of many smaller clusters as 
in early disease. 
In CHAPTER 5, we investigated an underlying pathophysiological mechanism by 
which this observed pattern of parenchymal destruction might arise.  We showed that cyclic 
stretch of lung tissue exacerbates the inflammatory response to cigarette smoke extract 
exposure, as characterized by increases in the pro-inflammatory cytokine IL-1b, which 




mechanical failure.  These are the first mechanotransduction data reported using an ex vivo 
PCLS model of emphysema, demonstrating the feasibility of using our system to probe 
such mechanisms and further, highlighting the physiological importance of recreating the 
dynamic environment of the lungs during tidal breathing in vivo.  Accordingly, we propose 
that the super cluster, given its enormous size and increased compliance, alters the 
biomechanical stresses and strains in surrounding healthy lung regions, increasing the risk 
of tissue failure and nearby parenchymal destruction.  These results subsequently suggest 
a mechanism linking overall lung decline, which proceeds over years to decades, to 
mechanotransduction-mediated changes in the local tissue environment, which occur 
within hours.  Moreover, they uniquely bridge the gap between earlier 2D power law 
analyses of emphysema distribution and the recent “lung at-risk” view of disease 
progression. 
In addition, these findings suggest that targeted intervention of mechanically 
abnormal lung regions could yield more effective treatment strategies.  This is most 
applicable to lung volume reduction, where resection or induced-contraction of affected 
lung tissue can drastically redistribute biomechanical forces within the lung.  Current 
efforts favor bronchoscopic alternatives (bLVR), which are less invasive compared to 
established surgical techniques (LVRS) but lack appropriate indications and optimal 
implementation strategies for the various approaches that have been proposed.  In 
CHAPTER 3, we compared both techniques in a computational model of emphysema 
progression, demonstrating how similar predicted outcomes and survival benefits between 




computational modeling in guiding patient-specific therapies and support the more 
widespread application of bLVR to benefit a more inclusive patient population. 
In summary, we bring together computational modeling, clinical imaging, and 
animals models in this dissertation to elucidate the role of biomechanical factors in the 
structural and functional lung decline in emphysema.  This work changes the narrative of 
COPD through compelling evidence highlighting biomechanical-inflammatory 
interactions as a key feature of disease progression.  We conclude, therefore, that future 
studies for therapeutics and disease processes must be considered within a framework that 
includes the local mechanical environment of the lung. 
 
6.2 Recommendations for Future Study 
Further areas of study will focus on treatments aimed at manipulating the balance 
of biomechanical forces in the parenchyma to slow lung decline and restore function.  
Linking the elastic spring network model to CT imaging would facilitate a priori estimates 
of bLVR treatment efficacy and allow for long-term predictions of patient outcomes.  In 
this case, multiple procedures could be simulated computationally to determine the optimal 
treatment strategy, which would deliver the greatest benefit in an individual patient.  This 
would provide a non-invasive and relatively economic assessment that is readily 
translatable to patient care.  Expanding this predictive model in 3D to include contributions 
of the super cluster would also help determine how targeted disruption of these 
characteristic structural defects could improve overall lung function.  It follows then, that 




whereby repair or structural reinforcement of the affected region could offer greater 
improvements in function over simple lung volume reduction.   
Additional insight to the pro-inflammatory mechanotransduction pathways could 
offer solutions to prevent or even reverse emphysema development.  The ex vivo platform 
described here was validated by characterizing changes in IL-1b; however, there are many 
other pro-inflammatory cytokines, including TNFa, IFNg, NF-kB, reactive oxygen 
species, and other interleukins, which exhibit similar mechanotransduction-mediated 
responses, including multiple downstream targets ranging from changes in gene expression 
to MMP activity.  Although the effects of cigarette smoke and other noxious particles are 
well characterized, the combinative effects in presence of cyclic stretch have yet to be fully 
described.  Moreover, studying PCLS from emphysematous lungs may reveal these acute 
and chronic responses are altered in disease.  Thus, future studies might define modifiable 
targets within this pathway that would confer the greatest protection against 





APPENDIX A– Real-Time Imaging of Lung Slices during Prescribed Stretch 
The stretcher device calibration from this study was published in PLoS ONE as part of a 
research article titled “Design of a Novel Equi-biaxial Stretcher for Live Cellular and 
Subcellular Imaging” [142].  Descriptions of the methods and results from this portion of 
the manuscript, which represent original work, are provided here.  Additional experiments 
using this system to stretch and image lung slices are also featured. 
 
A.1 Background 
PCLS offer a unique opportunity to characterize tissue mechanics at the alveolar 
level, and to study ex vivo the mechanisms underlying various lung diseases, such as the 
progressive nature of tissue destruction in emphysema.  However, relatively few techniques 
exist to investigate these mechanotransduction pathways in living tissue, particularly under 
dynamic stretch conditions that occur during breathing.  Here, we report the calibration of 
a single-well equibiaxial stretcher device, which we use to deliver prescribed stretch to 
living lung slices.  The primary aim of this project was to design and validate a method for 
live imaging of stretched PCLS at the scale of a single alveolus. 
 
A.2 Design and Calibration 
A.2.1 Methods 
The single-well stretcher device delivers prescribed area strains on an elastic 
membrane via vertical displacement over a cylindrical indenter (Figure A-1).  A center 




addition of media or buffer solution to maintain PCLS during live imaging.  To determine 
the relationship between the vertical displacement of the stage (indenter depth) and the 
change in surface area (ΔSA) of the membrane, we tracked the expansion and relaxation 
of a predetermined demarcated region on the membrane during quasi-static stretch.  A 
circular region was defined in the center of the membrane using acrylic paint (Pēbēo, 
Cedex, France) to mark sixteen dots enclosing a circle with diameter 27 mm.  To simulate 
the weight of media necessary for cell experiments, 10 mL of ddH2O was added to the 
membrane well.  The acrylic dots were then imaged continuously during quasi-static stretch 
as the depth of the indenter was increased from 0 to 20 mm with short pauses at depth 
increments of 2 mm.  Zero-depth was defined as the point of first contact between the 
membrane and ball bearings of the indenter, where a spacer between the travelling stage 
and base was used to establish a datum point for all subsequent experiments.  Custom image 
processing software (MATLAB, Mathworks, Natick, MA) was developed to segment the 
acrylic dots from the video recording and then track the change in area of the circular region 
they enclosed.  The ΔSA was thus defined as the percent area change of the region at each 
incremental indenter depth.  To determine whether the calibration changed over time, each 
membrane was stretched a total of 12 cycles with recordings acquired during cycle = 1, 2, 
3, 6, 12.  This was repeated for n=3 different membranes such that the final calibration was 
determined by their average.  Given this relationship between indenter depth and ΔSA, 
arbitrary strain waveforms could be generated with cycle-to-cycle variations.  
To characterize the frequency response of the device, sinusoidal waveforms were 




membranes at several frequencies and strain amplitudes.  A circular region was again 
defined on the membrane using the acrylic dots that were tracked using the imaging 
software as before.  Frequencies were logarithmically distributed over two decades 
between 0.01 and 1.00 Hz with area strain amplitudes of either 20 or 40% peak strain.  Each 
membrane (n=3) was stretched for 10 complete sinusoids for each frequency and 
amplitude.  Separate quasi-static stretch calibrations, as described above, were performed 
before and after sinusoidal stretching to confirm that deformation of the membrane did not 
occur subsequent to repeated stretching.  
To confirm that the strain applied at the length scale of the entire membrane well 
(i.e., macrostrain) was accurately translated to the strain experienced at the length scale of 
individual cells (i.e., microstrain), the membrane was first coated using Nile Red 
fluorescent high intensity beads (Spherotech, Lake Forest, IL) with diameters of 2.27 and 
5.1 µm.  Using the previously established ΔSA-indenter depth relationship, a prescribed 
macrostrain increasing from 0 to 40% strain was applied to the entire membrane while 
images of the beads were acquired during static stretch at increasing intervals of either 
2.5% or 5% strain using a Nikon Eclipse 50i fluorescence microscope with a Nikon Fluor 
60X water immersion objective.  From these images, some of the 2.27 µm beads were 
selected to be the vertices of a polygon and tracked at each strain level such that the ΔSA 
of the defined polygon was used to compute the local micro strain.  This procedure was 
then repeated at 9 different locations from 2 separate membranes to compare the measured 
microstrain to the prescribed macrostrain.  In addition, Delaunay triangulation and radial 




elastic membrane during stretch according to the relation given in Equation 5-1. 
A.2.2 Results 
Figure A-2A shows the nonlinear relationship between indenter depth and ΔSA 
measured at 2 mm increments from 0 to 20 mm of indenter depth.  Data points represent 
the average of three separate calibrations with different membranes. Standard deviations 
were too small to be plotted, with the largest standard deviation being 1.3%.  The unloading 
curve was also measured with a hysteresis between loading and unloading of only 2.9% 
(not shown).  These data demonstrate that the system is capable of reproducibly delivering 
strains of up to 80% across several cycles for a single membrane as well as between 
different calibrations.  Given this relationship between indenter depth and ΔSA, it is 
possible to generate stretch waveforms with prescribed strain amplitudes. For example, the 
prescribed and observed waveforms for a sinusoid with frequency 0.0464 Hz and strain 
amplitude 20% strain are shown in Figure A-2B.  The prescribed and delivered waveforms 
were nearly identical in shape, amplitude and frequency demonstrating the ability of the 
device to reproduce an arbitrary area strain waveform.  A similar behavior was observed 
across several frequencies and strain amplitudes.  Figure A-2C shows that the device has a 
flat frequency response over the range of 0.01 to 1.00 Hz at both 20% and 40% area strain.  
We also demonstrated that the microstrain measured at the length scale of 
individual cells matched the prescribed macrostrain applied at the length scale of the entire 
membrane.  The local microstrain was measured by imaging beads (Figure A-2D, left) that 
were used to define the vertices of a polygon (Figure A-2D, right) at baseline (green) and 




the micro strain sampled at 9 different locations from two separate membranes are 
compared to the prescribed macrostrain in Figure A-2E and observed to closely follow the 
line of identity.  The maximum standard deviation in microstrain for any prescribed 
macrostrain was found to be 0.75%.  As shown in Figure A-3, estimates of Lagrangian 
strain indicate equibiaxial stretch at the microscale with nearly identical 𝐸 and 𝐸 , and 
negligible 𝐸 . 
 
A.3 Precision-Cut Lung Slices 
PCLS from male Sprague-Dawley rats were collected and prepared as described 
previously in CHAPTER 5.  Individual slices were attached to the membrane with small 
beads of cyanoacrylate glue along the periphery, and then stretched quasi-statically from 0 
to 40% area strain in 10% increments.  Slices were stretched in HBSS to prevent drying of 
the sample.  Individual alveoli were tracked using brightfield microscopy, while images 
were obtained using a Nikon Fluor 20X water immersion objective at each stretch level.  
Alveolar perimeters were manually-selected using a custom MATLAB script to calculate 




∙ 100% Equation A-1 
where 𝐴o,5 and 𝐴o,W are the stretched and original alveolar areas, respectively. 
Representative brightfield images of an individual alveolus during stretch are 
shown in Figure A-4.  To determine whether alveolar area followed changes in membrane 




softening after the first stretch; however, ∆𝐴o closely followed the prescribed strain for 
subsequent stretch cycles.  These findings not only demonstrate that changes in alveolar 
strain reflect prescribed membrane strain, but they are consistent with repeated stretching.  
This is an important consideration for applications with cyclic stretch of lung slices.  
Additional fluorescent images of PCLS during stretch are shown in Figure A-5.  
 
A.4 Summary 
Our single-well tissue stretcher provides a useful technique for delivering 
reproducible, equibiaxial stretch of living PCLS.  We show that prescribed area strains of 
the elastic membrane are consistent at the microscale and further, are translated to area 
changes of individual alveoli.  Combined with the live tissue imaging demonstrated here, 
this system allows for future work to investigate mechanotransduction pathways at the 









Figure A-1.  Schematic of the single-well tissue stretcher device.  The membrane 
is fixed between two metal rings and fastened to the actuating stage, which is 
displaced vertically around the indenter to apply stretch, while ball bearings 
provide for smooth continuous stretch.  The indenter is hollow to allow for live-






Figure A-2.  (A) Nonlinear relationship between the indenter depth and the corresponding change 
in surface area of a demarcated region on the membrane; this calibration curve was subsequently 
used to prescribe strain waveforms as a function of indenter depth.  Data points represent the 
average of n=3 calibrations with different membranes; standard deviation bars (not shown) are 
smaller than symbols.  (B) Representative sinusoidal waveform applied to membrane (amplitude, 
20% strain; frequency, 0.0464 Hz), the input waveform (solid line) and the observed change in 
surface area (open circles) are shown demonstrating close agreement between input and 
measurement.  (C) Frequency response of the device is flat for stretch frequencies between 0.01–
1.0 Hz; sinusoidal waveforms with prescribed strain amplitudes of 20% (filled triangles) and 40% 
(open squares) are shown with reference lines, error bars represent the standard deviations (n=3).  
(D) Left: characteristic image of marker beads used to track micro strain; Right: detection algorithm 
showing beads at baseline (green) and after applied strain (magenta), specific beads are tracked and 
the areas enclosed by their polygons are used to determine the corresponding micro strain.  (E) 
Change in micro strain closely follows the prescribed macrostrain, line of identity is shown for 



























































Figure A-3.  Left: equibiaxial stretch was confirmed at the microscopic scale as equivalent normal 
strains (Exx and Eyy) were observed with negligible shear strain (Exy).  Right: schematic of strain 
estimation.  Selected beads formed vertices for Delaunay triangulation in the calculation of the 






Figure A-4.  Left: representative sequence of alveolar stretch with live imaging is 
shown during loading and deloading.  Right: Measurements of area strain were 
reproducible across multiple cycles of stretch in an individual alveolus following 













APPENDIX B – Structural Predictor of Emphysema Progression 
This theoretical work was presented as a platform presentation titled “A Novel Structural 
Predictor of Emphysema Progression Using a Network Model of Lung Tissue 
Deterioration” at the 2016 BMES Annual Meeting in Minneapolis, MN. 
 
B.1 Background 
Astrophysicists have long referred to a “guiding principle” that motivated the 
discovery of universal physical properties ranging from gravitational waves to the speed of 
light; however, no such picture exists to concisely summarize emphysema progression.  A 
myriad of disease models exists ranging from enzymatic tissue digestion to direct smoke 
exposure (see section 2.5), yet all eventually yield the same pathology – progressive, force-
based destruction of the lung parenchyma.  Moreover, static CT images contain only 
structural information, wherein emphysematous lung regions appear as contiguous low-
attenuation pixels (2D), or voxels (3D), which we refer to as clusters.  Consequently, 
estimates of the local mechanical environment must be derived from underlying 
assumptions.  Without a guiding principle for disease progression, the ability to predict the 
spatial deterioration of lung tissue thus remains elusive. 
Continuing with the metaphor above, we conjecture that emphysema clusters 
mimic planetary bodies exerting forces on the surrounding parenchyma, similar to gravity, 
where the summation of forces at a specific point represents the local probability of healthy 
tissue becoming emphysematous (Figure B-1).  Although emphysema clusters correspond 




cluster [15], [16].  Thus, we consider here whether such a theoretical construct can lend 
insight to the prediction of parenchymal destruction in emphysema.  We present the 
derivations for the governing equations, which are subsequently implemented in a 2D 
elastic spring network model of progressive tissue failure. 
 
B.2 Theory 
The governing relation determining the risk of emphysema, 𝐼, in a single CT pixel, 
which is attributable to an individual cluster, depends on the following three features: (1) 
cluster size, 𝐴; (2) distance of the pixel away from the cluster, 𝑑; and (3) the angle, 𝜑, of a 
straight line drawn between the pixel and the centroid of the cluster relative to the major 
axis of the cluster.  The model assumes clusters are roughly ellipsoidal in shape, with 
definable major and minor axes.  Briefly, risk increases with 𝐴 and decreases with 𝑑, while 
risk is highest along the perimeter near the vertices.  As a starting point, we consider for 




𝑟:  Equation B-1 
where 𝐺 is the gravitational constant, 𝑚 and 𝑚: are the masses of the two objects, and 𝑟 
is the Euclidean distance between them.  For a CT image, 𝑚 is the unit mass of the 
selected pixel with area of 1, such that 𝑚: is equivalent to the total number of pixels in the 
cluster, 𝐴.  In place of 𝐺, we also introduce the function 𝑓(𝜑) to reflect the angle relative 






𝑑: Equation B-2 







: 𝜑 Equation B-3 
where 𝑎 and 𝑏 are the major and minor axes of the cluster.  The above function is best 
visualized by comparing the risk profiles proceeding from circular and ellipsoidal clusters, 
as shown in Figure B-2. 
To account for potentially unequal, relative contributions of each feature, we 












sin: 𝜑¥ Equation B-4 
Then, summing over 𝑁 clusters in the image and including a vertical gradient to simulate 
gravity, 𝑔, gives the final risk of emphysema for a single CT pixel as follows: 

















 Equation B-5 
 
B.2.1 Elastic Spring Network Simulation 
To test this relation, we generated a representative 2D spring network model, which 
has been described in detail in section 3.4.2, with holes of various sizes representing 
emphysema Figure B-3A.  The network was thresholded to generate an apparent CT image 
(not shown) and the local risk of tissue failure for the entire image was estimated by 




indicated by red, were then broken.  The spring network and the predicted risk image were 
converted to a 128x128 grid.  Boxes corresponding to the 98th percentile or higher were 
considered “high-risk” for tissue failure.  Comparing the high-risk areas with the gridded 
locations of spring breaks (Figure B-3B) demonstrated that the majority of spring elements 
failed in the predicted areas.  
 
B.3 Generalized Form 
As shown above, a strong correlation was observed between locations of spring 
breaks and areas of high risk predicted.  However, continued breaking of spring elements 
lead to more irregular shaped clusters, similar to CT images [17].  To account for these, we 
replace 𝑓(𝜑), which assumes an ellipsoid, with the local curvature along the perimeter of 
the cluster, 𝜅, which gives a more generalized form as follows: 







 Equation B-6 
where the curvature can be expressed in polar coordinates as follows: 
𝜅(𝜃) =
𝑅: + 2𝑅¬: − 𝑅	𝑅¬¬
­𝑅: + 𝑅¬:®
¯ :⁄  Equation B-7 
B.3.1 Disease Progression 
To assess the generalized form in Equation B-6, we used the same approach as 
described above; however, we simulated disease progression over three steps representing 
follow-up CT, while evaluating efficacy for a range of exponent values at each stage 




in predicting the locations of tissue failure, which was represented here by broken spring 
elements.  This suggests that functional information may be derived from purely structural 
information, provided an underlying assumption of how emphysema clusters affect 
neighboring tissue, which we conceptualized as gravitational interactions among planetary 
bodies.  Future work will determine whether this technique can be applied to CT images in 
patients with emphysema.  Such a breakthrough would have the potential to optimize 
treatments by targeting high-risk lung regions with the aim of preventing emphysema 
development before it progresses. 
 
B.4 Limitations 
Of course, there are limitations with this theoretical exercise.  First, only 
mechanical forces are considered for disease progression, while synergistic effects of 
inflammation are ignored.  We use a static, 2D model that does not incorporate the effects 
of large airways and vessels, or heterogeneous tissue stretch during breathing.  Similarly, 
the boundary conditions are symmetric and well-defined in this simulation, which is not 
the case in the human lung.  Nevertheless, these findings provide a conceptual framework 










Figure B-1.  Emphysema clusters contribute to the risk of healthy 








Figure B-2.  Each cluster exerts a field effect throughout the entire image, while a vertical gradient 
(top right) simulates gravity.  Their superposition yields the final field equation for every pixel in 







Figure B-3.  (A) Elastic network and corresponding predicted risk.  Red 
corresponds to elements carrying high forces, while lower forces are indicated by 
blue.  (B) Discretized risk map and corresponding hit map based on the location of 







Figure B-4.  (A) Simulated disease progression in the elastic network and corresponding predicted 
risk images.  (B) Sensitivity over a range of exponent a and g values given b=1.  (C) Sensitivity 
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